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 My PhD research included two distinct projects. Project I examined the 
transcriptional regulation of two genes expressed in the retina, synaptotagmin 11 (Syt11, 
retinal ganglion cell-enriched) and S-antigen (Sag, photoreceptor-enriched). For each, a 
cloned fragment was identified that showed promoter activity in its respective cell 
population. A deletion analysis and subsequent bioinformatic analysis were used to 
predict transcription factors (TF) binding within the region of interest, and then binding 
site mutant promoter-reporter constructs were generated and tested. Finally, siRNA 
knockdown of TFs of interest was followed by endogenous expression analysis. I 
identified regions of interest for each gene (Syt11 -192 to -41 bp and Sag -279 to -182 bp) 
but knockdown of multiple TFs in each cell population yielded inconclusive results. 
In Project II, I evaluated sunitinib, a multiple kinase inhibitor that is neuroprotective 
for retinal ganglion cells, for its ability to promote photoreceptor (PR) survival in mouse 
models of PR degeneration. Based on the findings of a collaborator who found that 
sunitinib promoted the survival of PRs in a rat model of an autosomal dominant retinal 
degeneration (Rho S334ter), I studied the retinal expression of dual leucine kinase (DLK) 
protein (known to be a target of sunitinib) during retinal degeneration (RD). I observed 
an increase in DLK abundance in degenerating retinas, which persisted after most PRs 
had degenerated, suggesting that DLK accumulation occurs, at least in part, in a cell type 
other than PRs. I tested the effect of sunitinib on photoreceptor survival in the Rho 
Q344ter and the rd1 (Pde6b mutant) mouse RD models, but under the conditions tested 
did not observe evidence of increased PR survival. Additionally, I tested the ability of 
genetic deletion of Parp1 to promote PR survival in the sodium iodate and rd1 mouse 
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models of RD. Parp1 null PRs did not show evidence of increased survival at 36 days 
post sodium iodate administration. Several litters of Parp1 KO/rd1 animals had increased 
PR survival. Further studies are needed to more fully define the potential role of 
sunitinib, DLK inhibition, and PARP1 inhibition in photoreceptor neuroprotection. 
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The retina is the multilayered neural tissue that lines the back of the eye and is 
responsible for converting light into a neurochemical signal. The two most medically 
relevant cell types are photoreceptors and retinal ganglion cells. The photoreceptors 
(PRs), the rods and cones, are the cells responsible for converting a light signal into a 
chemical signal that is then passed through the rest of the retinal cells and eventually 
through the retinal ganglion cells to the brain. Photoreceptors are medically relevant 
because they are affected by numerous genetic and degenerative diseases such as retinitis 
pigmentosa and age-related macular degeneration. Retinal ganglion cells are damaged in 
glaucoma and other forms of optic nerve disease, and it is their loss that leads to vision 
loss and potentially blindness in these diseases, and thus they are also medically highly 
relevant. 
Rods, which are more sensitive than cones and are responsible for vision in dim 
light, are the most numerous photoreceptor-type in most mammalian retinas, and they 
express the rhodopsin visual pigment. Cone photoreceptors are responsible for bright 
light, high acuity and color vision. There are several different types of cone 
photoreceptors characterized by which of several different cone opsin visual pigments 
they express. Individual cones, with a few exceptions, express only one visual pigment, 
and the opsin they express dictates the wavelengths of light to which they are most 
sensitive. 
Phototransduction is the extensively studied and remarkable process by which 
light is converted into a chemical signal within photoreceptor cells (reviewed by Sung & 
Chuang [1]). Mammalian opsin molecules, with a few exceptions, are covalently linked 
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to the chromophore 11-cis-retinal. The phototransduction process begins when light 
photo-isomerizes 11-cis-retinal to all-trans-retinal within photoreceptor cell membranes, 
causing a conformational change in rhodopsin and initiating a G protein coupled 
signaling pathway. Transducin, a G protein, is activated by rhodopsin that in turn 
activates phosphodiesterase which hydrolyzes cGMP. The decrease in cGMP closes the 
cGMP-gated channels and causes the photoreceptor to hyperpolarize, which decreases the 
amount of glutamate being released at synapses with second order retinal neurons. These 
signal changes are ultimately conveyed to the brain where visual perception takes place. 
Photoreceptors are affected in a large number of degenerative diseases. Age-
related macular degeneration, which is the most common cause of irreversible blindness 
in the elderly in the Western world, is an example of a degenerative disease that affects 
PRs and their major supporting cells, the retinal pigment epithelial (RPE) cells. Retinitis 
pigmentosa and Leber congenital amaurosis (LCA) are genetically heterogeneous groups 
of retinal degenerative diseases caused by a wide spectrum of genetic mutations that 
affect PR and RPE cells. LCA can be considered a more severe form of RP that affects 
young children. The degree and rapidity of vision loss in LCA and RP are variable, but 
many forms of these diseases ultimately result in blindness. Many of the genes, of which 
there are more than 200, that when mutated cause retinal degenerative disease, encode 
proteins that are involved in phototransduction, the visual cycle or transcription factors 
that regulate the expression of phototransduction proteins (RetNet, 
http://www.sph.uth.tmc.edu/RetNet/).  
Retinal ganglion cells (RGCs) receive and integrate visual information from other 
cells in the retina and transmit this information via the optic nerve to visual centers in the 
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brain. A variety of diseases cause damage and loss of RGCs, which can result in vision 
loss and blindness. Among these diseases, the neurodegenerative disease glaucoma is the 
most common.  Approximately 60 million people have glaucoma, and behind cataracts, it 
is the second leading cause of blindness in the world [2]. Despite the implication of 
multiple cellular mechanisms and pathways as contributing to glaucoma-associated RGC 
cell damage and death, including excitotoxicity, ischemia, oxidative stress, neurotrophin 
deprivation due to impaired retrograde transport, glial cell changes, and altered local 
immune status [3], the treatment of glaucoma continues to be based almost solely on the 
reduction of intraocular pressure [4-6]. A potentially more attractive approach would be 
to target damage-promoting pathways specifically in RGCs.  
Developments of cell-type specific therapeutic approaches are greatly facilitated 
by understanding the gene expression regulatory pathways in the particular cell of 
interest. The identity and normal functioning of a tissue is dictated by differential gene 
expression of the cells that make up that tissue. The development of all six of the retinal 
neurons (RGCs, rods, cones, horizontal cells, bipolar cells and amacrine cells) and retinal 
glial cells (Müller glial cells) has been studied extensively in a number of species 
(reviewed by Xiang [7]). A number of transcription factors necessary for retinogenesis 
have been identified, including PAX6, RX, CHX10 and SIX3 [8]. PAX6, in particular, is 
required early on in cells of the developing visual field [9, 10], and in fact when it is 
genetically deleted, only amacrine cells develop [9]. Photoreceptor development, in 
particular, and its myriad necessary transcriptional regulatory events, has been studied in 
great detail (recently reviewed by Swaroop [11] and Ranganathan & Zack [12]). In the rat 
and mouse retina, cone and then rod photoreceptors are born beginning at embryonic 
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days 11.5 and 12, respectively, and continue to be born and develop until embryonic day 
17.5 for cones and post-natal day 10 for rods [13, 14].  
The sequential appearance of several transcription factors (RAX then OTX2 then 
CRX) is necessary for the initial photoreceptor cell fate specification and differentiation 
[15-17]. The presence of the ROR! transcription factor in photoreceptor precursor cells is 
necessary for the eventual rod photoreceptor cell fate as it goes on to stimulate the 
expression of Nrl, another necessary transcription factor, which in turn stimulates the 
expression of Nr2e3 [18-21]. The combination of NRL and NR2E3 is necessary for rod-
specific gene expression and differentiation, and in the absence of NRL, photoreceptor 
precursor cells differentiate into cone photoreceptors [20]. The combination of CRX and 
NRL transcription factors is necessary for the expression of many different rod 
photoreceptor specific genes [22, 23]. Cone photoreceptor development diverges from 
that of rods through the actions of a number of transcription factors, which not only 
specify cone fate, but exact type of cone fate through the stimulation of transcription of 
the various cone opsin genes. In the absence of NRL, CRX and ROR! act together to 
promote the expression of S-opsin and the development of short wavelength (or blue) 
cones [24]. However if TR!2 is present with its ligand, thyroid hormone, then M-opsin is 
expressed and the precursor cell develops into a medium wavelength (or green) cone 
[25]. 
Although not as well studied as PRs at the gene regulation level, in recent years 
there has been increasing attention to the study of the mechanisms regulating RGC-
specific gene expression. Broad regulatory pathways involved in RGC cell fate 
determination have been defined in the developing murine retina, and a number of the 
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transcription factors that are important for RGC development have been identified [7]. 
Transcriptomic studies of RGC changes associated with RGC damage have also been 
performed in animal models of glaucoma [26, 27].  
RGCs are the first cell type to be born during retinogenesis, and many of the 
necessary transcription factors and their regulatory network have been established. Of 
note, however, is that there are many different types of RGCs in the developed retina that 
have followed various gene regulatory pathways to become fully differentiated RGCs, 
necessitating a complicated gene regulatory network. As mentioned earlier, PAX6 is 
required not only for retinal progenitor determination, but specifically for RGC 
determination [9]. It is known that PAX6 and the Notch pathway have opposite effects on 
RGC development, and NOTCH inhibits Math5 expression, thus inhibiting RGC 
development [28]. Additionally, when Neurod1, which is required for amacrine cell 
development, is replaced with Math5, amacrine cell fate is prevented and RGC cell fate is 
promoted [29]. It is known that the ATOH7/MATH5 transcription factor, which is in part 
dependent on Pax6 expression [8, 9, 30-32], is important for RGC development, 
however, not all cells that express Math5 will become RGCs [33, 34]. Additionally, there 
is a subset of RGCs that never express Math5 [35], and instead, expressed Neurod1 [36]. 
Nonetheless, targeted disruption in mice results in a reduced number of RGCs and the 
absence of an optic nerve [37, 38].  
MATH5 regulates the transcription of several other genes including islet 1 (Isl1), 
Eya2 and Pou4f2/Brn3b that are critical for continued RGC development and 
maintenance [30, 39, 40]. Retina-specific knockdown of Isl1 expression in the developing 
mouse retina did not prevent RGC development, but did result in early RGC apoptosis 
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[30]. In this Isl1 knockdown experiment, the expression of Brn3b was also decreased, 
suggesting Isl1 lies upstream of Brn3b [30]. The POU domain transcription factors, 
POU4F2/BRN3B, POU4F1/BRN3A and POU4F3/BRN3C are necessary for RGC 
differentiation, maturation and axon growth [41, 42]. BRN3B regulates a number of other 
genes including transcription factors with known or postulated roles in the retina as well 
as genes important for neuron function and integrity [31, 43]. And not unexpectedly, 
additional players in the retinal and RGC gene regulatory network are being discovered 
constantly. A recently identified pair of redundant factors (ONECUT1 and ONECUT2) 
are important for early retinal cell differentiation and double knockout of both factors 
resulted in abnormal horizontal cell, cone cell and RGC development [44]. 
A number of gene expression studies have examined whole retina gene expression 
changes in glaucoma [27, 45, 46] and found an up-regulation in inflammatory and glial 
activation-related genes including C1q and Gfap. One study that examined laser capture 
microdissected RGCs after glaucoma induction found an up-regulation of genes in 
apoptosis-related pathways and markers of inflammation, including complement 
pathways (e.g. Gfap, C1qa, C1qb, C3) and a down-regulation of neuronal pro-survival 
genes (e.g. Stmn2, Ywhaz, Vsnl1, Ywhab, Ret) [26]. Although many RGC transcriptional 
pathways have been identified, many molecular details are lacking.  
Though some of the pathways directing the development of photoreceptors and 
RGCs have been elucidated, the exact transcription factors necessary to direct expression 
of the many different photoreceptor- and RGC-specific genes have not been fully 
determined. This is an important area of research and advances in post-development 
transcriptional regulation in these cells could support a number of important pursuits 
8 
!
including gene therapy, stem cell therapy, and neuroprotective drug discovery. Knowing 
what regulatory sequences are required for cell-specific expression would allow cell type-
specific gene therapy to be directed to photoreceptors or RGCs within the retina, and 
would allow regulating the expression of the gene therapy target genes or neuroprotective 
genes. Additionally if the regulatory sequences of genes known to contribute to either 
photoreceptor or RGC survival or death were known, then a screen for drugs that 
modulate the expression of these genes could be used to identify important novel 
treatment approaches for diseases that affect these cells.  
Retinal transcriptional regulation has often been studied using immortalized cell 
lines. For example HEK293, COS, and Y79 cells have been used to study photoreceptor 
promoters [47-51] and RGC5 cells have been used to study a number of aspects of RGC 
biology [52]. However, although such studies have yielded useful information, 
immortalized cells, even if originally from the cell type of interest, can differ greatly from 
the actual cell in a living tissue. For example, the network of other transcription factors 
and modulators as well as the epigenetic status of primary cells compared to 
immortalized cells can differ significantly [53]. Related to these differences, promoter 
reporter activity can also differ in primary cells compared to immortalized cell lines, 
making the discernment of cell-type specific transcriptional regulatory mechanisms 
difficult [47]. Therefore, although their use is more technically challenging, for the retinal 
promoter studies described in the next two chapters I chose to use primary retinal cells 
because they more accurately recapitulate the in vivo genetic and cellular milieu of the 
retina and thus are better suited to study of the mechanisms that determine cell type-
specific gene expression in the retina. Chapter 2 describes studies utilizing synaptotagmin 
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11 (Syt11)-reporter constructs in combination with purified murine RGCs as a model to 
study RGC transcriptional regulation. Chapter 3 describes parallel studies utilizing S-
antigen (Sag)-reporter constructs in combination with total mouse retinal cultures, which 
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As stated earlier, transcriptional regulation allows a cell to express particular 
genes so it can function properly in its tissue-specific milieu. Identification of the precise 
regulatory DNA sequences required for RGC-specific expression would allow RGC-
directed expression of potential therapeutic molecules within the retina, and perhaps even 
within specific subsets of RGCs.  Additionally, RGC-specific reporters or reporters 
specific to RGC death/survival pathways can be used in screens for neuroprotective 
factors. We and others have been working to define the cis-acting elements that regulate 
RGC-specific transcriptional activation. Here we describe the process by which we have 
worked to define the regulatory elements that control expression of a model RGC-
expressed gene, synaptotagmin 11 (Syt11).   
Transcriptional regulation is often studied using immortalized cell lines, but even 
if originally derived from the cell type of interest, immortalized cell lines often differ 
significantly from the actual cell type of interest in terms of their gene expression patterns 
and transcription factor networks. For this reason, we chose to develop and utilize a 
protocol for transient transfection of primary rodent retinal ganglion cells for our 
promoter studies. Using this protocol, we defined some of the regulatory sequences 
important for Syt11 expression in RGCs, and utilized siRNA knockdown to begin an 




Materials & Methods 
Enrichment of Primary Rodent Retinal Ganglion Cells 
All animals were treated in accordance with the ARVO statement for the care and 
use of animals and all procedures were approved by the Johns Hopkins University 
Institutional Animal Care and Use Committee. The retinal ganglion cell (RGC) 
enrichment procedure was adapted from Barres et al [1].  
 
Digestion 
In brief, neonatal pups (postnatal day 0-3) were euthanized on wet ice and eyes 
enucleated. Retinas were isolated from the globes in cold CO2 independent media 
(catalog # 18045-088, Life Technologies, Carlsbad, CA) containing  2 mM L-glutamine 
(catalog # 25030-081, Life Technologies, Carlsbad, CA) and 50 U/mL / 50 µg/mL 
penicillin/streptomycin (catalog # 15070-063, Life Technologies, Carlsbad, CA). Retinas 
were rinsed in PBS without Ca2+ or Mg2+ (catalog # 10010-023 Life Technologies, 
Carlsbad, CA) and then digested in 1 mL/10 retinas of activated papain containing 250 
U/mL DNase I (catalog # D4527, Sigma-Aldrich, St Louis, MO) and pH adjusted to 7.4. 
Papain (16.5 U/mL for pup retinas & 33 U/mL for adult retinas, catalog # LS003119 
Worthington, Lakewood, NJ) was prepared in Hibernate-E without Ca2+/Mg2+ (catalog # 
HE-Ca 500ml, Brainbits, Springfield, IL) activated with 0.2 mg/mL L-cysteine (catalog # 
C7352 Sigma-Aldrich, St Louis, MO) and the  pH adjusted to 7.4 with NaOH. Retinas 
are digested for approximately 40 minutes, at which time the tissue has dissociated into a 
cell suspension. The digestion was inhibited with 0.5 mL of a soybean trypsin inhibitor 
solution containing 15 mg/mL soybean trypsin inhibitor (catalog # LS003587, 
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Worthington, Lakewood, NJ), 15 mg/mL bovine serum albumin (BSA) (catalog # 
126579, Merck KGaA, Darmstadt, Germany) and 125 U/mL DNase I (catalog # D4527, 
Sigma-Aldrich, St Louis, MO) in Hibernate-E (catalog # A12476-01, Life Technologies, 
Carlsbad, CA) per 1 mL of the papain solution and the cell suspension was triturated 
drop-wise six times with fire polished siliconized glass pipettes to generate homogeneous 
single cell solution.  
 
Macrophage depletion 
Cells were spun down at 80 x g for 7 minutes and resuspended in 1.8 mL DPBS 
with glucose and pyruvate (catalog # 14287-080, Life Technologies, Carlsbad, CA) 
containing 0.2% BSA and then incubated with anti-CD11b antibody-coated (catalog # 
554859, BD Biosciences, San Jose, CA) magnetic beads (Cellection pan mouse IgG, 
catalog #11531D, Life Technologies, Carlsbad, CA) with gentle rotation for 15 minutes 
at room temperature. The CD11b bead-bound macrophages and remaining beads were 
then depleted from the cell suspension using a magnet. Supernatant cells were 
resuspended in 13 mL DPBS with glucose and pyruvate containing 0.2% BSA and 
applied to a pre-made immunopanning plate. 
 
Positive selection of RGCs using immunopanning 
Immunopanning plates were created  by coating a 10 cm non-cell culture treated 
petri dish with 70 mg of a goat anti-rat IgG for rat RGC immunopanning (catalog # 112-
005-003, Jackson Immunoresearch, West Grove, PA) or a goat anti-mouse IgM for 
immunopanning mouse RGCs (catalog # 115-005-020, Jackson Immunoresearch, West 
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Grove, PA) and then 30 mg of an anti-Thy1.1 IgG for rats (catalog # MAB1406, Merck 
KGaA, Darmstadt, Germany) or an anti-Thy1.2 IgM for mice (catalog # MCA02R, Abd-
Serotec, Raleigh, NC). The plate was gently agitated every 15 minutes during a one to 
two hour incubation at room temperature. The supernatant (RGC-depleted) was then 
removed and discarded and the plate washed 5-7 times with 5 mL of DPBS with glucose 
and pyruvate (total of 35 mL). The adhered RGCs were gently scraped off with a cell 
lifter (catalog # 83-3008, Corning, Tewksbury, MA) in 10 mL of Hibernate-E without 
Ca2+/Mg2+ (catalog # HE-Ca 500ml, Brainbits, Springfield, IL) containing 10% Fetal 
Bovine Serum (catalog # 16140-071, Life Technologies, Carlsbad, CA). RGC enriched 
cells were then counted and plated at a density of 10,000 to 20,000 cells / well in 96 well 
poly-d-lysine-coated plates. The yield was typically 20,000 to 30,000 cells / mouse retina 
and 50,000 to 70,000 cells / rat retina. Cells were cultured in Neurobasal (catalog # 
21103-049, Life Technologies, Carlsbad, CA) containing B27 supplement (catalog # 
17504-044, Life Technologies, Carlsbad, CA) 2 mM L-glutamine , 50 U/mL / 50 µg/mL 
penicillin/streptomycin, forskolin (2.5 uM for rats, 5 uM for mice) (catalog # F3917, 
Sigma-Aldrich, St Louis, MO) and sunitinib (1 uM for rats, 0.5 uM for mice) (catalog # 
S-8803, LC Labs, Woburn, MA) to promote RGC survival (work of Zhiyong Yang, 
unpublished data). Cells were incubated at 37oC in a humidified incubator containing 5% 
CO2. 
 
Promoter Reporter Creation (initial set, deletion series, binding site mutants) 
Genomic DNA was isolated from Sprague-Dawley rat liver using a QIAmp DNA 
Mini Kit (catalog # 51304, Qiagen, Germantown, MD) and a fragment of the upstream 
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promoter region of solute carrier family 17 (sodium-dependent inorganic phosphate 
cotransporter), member 6 (Slc17a6), was PCR amplified and recombined in pDONR221 
using the Gateway® system (BP Clonase II, catalog # 11789-020, Life Technologies, 
Carlsbad, CA). Promoter region fragments from published rat neurofilament medium 
(Nefm), neuritin 1 (Nrn1), peripherin 1 (Prph1), semaphorin 6b (Sema6b), synuclein 
gamma (Sncg) and synaptotagmin 11 (Syt11) were synthesized (GenScript, Piscataway, 
NJ) and provided in Gateway® compatible plasmids. See Table 1 for PCR primers and 
lengths of promoter regions. Gateway LR recombination reactions were performed to 
insert promoter fragments into a Gaussia luciferase gene promoter reporter Gateway® 
destination vector (pGluc) using the LR Clonase II from Life Technologies (catalog # 
11791-019). The pGLuc vector was created by inserting the Gateway® reading frame 
cassette upstream of the Gaussia luciferase reporter gene in the pGLuc-Basic 2 vector 
(catalog # N8082S, New England Biolabs, Ipswich, MA). Insertion and proper 
orientation in entry and destination vectors were confirmed with colony PCR and 
sequencing with a forward primer within the vector upstream of the recombination site 
and a reverse primer within the insert.  
The Syt11 promoter deletion series was constructed by PCR amplifying fragments 
of the upstream region from rat genomic DNA and cloning them into pENTR (catalog # 
K2400-20, Life Technologies, Carlsbad, CA). Constructs were confirmed by sequencing 
and the insert recombined into the pGLuc destination vector using the Gateway® system.  
See Table 2 for primers used in the construction of the deletion series and fragment 
lengths. Length of insert and correct orientation within the pGLuc vector was confirmed 
by colony PCR. 
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Binding site mutants were created in the full length (-656 to +136 bp) Syt11 
promoter reporter in the pENTR vector using Life Technologies’ Geneart® mutagenesis 
system by introducing transversions for each nucleotide within the predicted binding site. 
The overlapping nucleotides of the DEAF1 and SP1 binding sites were left unmutated 
when only the DEAF1 motif or only the SP1 motif were mutated, but mutated when the 
two sites were mutated together. The binding site mutations in the pENTR vector were 
confirmed by sequencing. See Table 3 for primers used. The DEAF1 sites were mutated 
in two steps because of their length and constraints of the Geneart® system. Constructs 
were recombined into the previously mentioned pGLuc vector using the Gateway® 
system (Life Technologies, Carlsbad, CA) and insert presence & orientation were 
confirmed via colony PCR. The full length (-656 to +136 bp), wild type Syt11 promoter 
fragment was also recombined into a Cypridina luciferase (another secreted luciferase, 
CLuc) containing reporter plasmid which had been created by the insertion of a 
Gateway® site upstream of the CLuc gene (pCLuc, New England Biolabs, Ipswich, MA), 
which was used as a transfection control. 
Plasmids were transformed into and grown in E. coli in batches and isolated using 
either Promega’s PureYield Midiprep system (catalog # A2492, Madison, WI) or Life 
Technologies’ HiPure Plasmid Filter Maxipreps (catalog # K2100, Carlsbad, CA) and 
resuspended and stored in tris-EDTA buffer. 
 
Testing of Promoter Reporters 
Initially (Figure 2), promoter reporters were electroporated into isolated rat RGCs 
using Invitrogen’s Neon system. In brief, RGCs or dissociated whole retinal cells were 
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resuspended in the Neon electroporation buffer R and electroporated in 10 µL with 0.5 
µg plasmid at 1100 V, 30 msec, 1 pulse. After electroporation, cells were gently squirted 
into wells already containing warmed & equilibrated growth media. There were always 
three or four replicate wells for each construct. Electroporation using the Neon system 
resulted in approximately 30-40% transfection efficiency with significant cell mortality. 
Later, constructs were transfected into RGCs using NeuroMag (OZ Biosciences, 
San Diego, CA) (Figures 3 and 6). NeuroMag (0.2 µL) was complexed with 200 ng of 
plasmid in OptiMem (catalog # 31985-088, Life Technologies, Carlsbad, CA) and added 
to wells containing 10,000 to 15,000 RGCs/well in growth media in a 96 well plate, 
which was then placed on the OZ Biosciences magnet (catalog # MF14000) overnight in 
a cell culture incubator. Typically each well was transfected with the pGLuc construct of 
interest and a pCLuc construct (SV40- or CMV- CLuc or full length, wild type Syt11-
pCLuc), which was used to normalize the transfection. Transfection efficiency using 
NeuroMag was lower than electroporation and was usually around 10% with less cell 
mortality. 
Media aliquots to measure luciferase activity were collected at 48 or 72 hours 
post-transfection and assayed separately using Gaussia and Cypridina luciferase assay 
kits from New England Biolabs (Ipswich, MA). For Figures 3 and 6 the constructs’ GLuc 
activity was normalized to the activity of a co-transfected pCLuc construct (SV40-CLuc 
for Figure 3, Syt11 -656 to +136-pCLuc for RGCs and SV40-CLuc for 293 cells in 
Figure 6 and CMV-CLuc for Figure 8). Empty vectors (Basic-CLuc and Promoterless-




RNA collection and cDNA conversion 
For Figures 1 and 10, RNA was collected from dissociated whole retinal cells and 
immunopanned RGCs immediately after being scraped off the immunopanning plate 
from early post-natal Sprague-Dawley rat pups and adult rats using Qiagen’s Mini 
RNeasy kit (catalog # 74104, Germantown, MD) including an on-the-column DNase 
treatment using Qiagen’s RNase-free DNase set (catalog # 79254). RNA was quantified 
using a Nanodrop (ThermoScientific, Wilmington, DE) and 100-500 ng converted to 
cDNA using random primers and the Applied Biosystems High Capacity cDNA Reverse 
Transcription Kit  (catalog # 4368814, Life Technologies, Carlsbad, CA). For siRNA 
knockdown experiments (Figures 7, 8B, 11, 12 and 13) RNA was collected from plated 
RGCs using Qiagen’s Micro RNeasy kit (catalog # 74004) and all of the RNA collected 
was converted to cDNA without quantification using random primers using the 
aforementioned cDNA reverse transcription kit (catalog # 4368814, Life Technologies, 
Carlsbad, CA).  
 
Quantitative Real Time-PCR (qPCR)  
Sequences of primers used in qPCR assays are listed in Table 4 and came from 
RT Primer database (http://medgen.ugent.be/rtprimerdb/) or designed with Roche’s 
primer design algorithm 
(http://lifescience.roche.com/shop/CategoryDisplay?catalogId=10001&tab=Assay+Desig
n+Center&identifier=Universal+Probe+Library&langId=-1#tab-3). Primer pair 
efficiencies were determined using a standard curve of RGC cDNA and deemed adequate 
if they were between 90 and 110%.  Samples were run in triplicate in a BioRad Cfx 
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C1000 384 qPCR machine in a total reaction volume of 8uL containing 0.04 µL of cDNA 
for gene survey (Figures 1 and 10) and 0.2 uL cDNA for siRNA KD experiments 
(Figures 7, 8, 11, 12 and 13), 125 nM of each primer, EvaGreen (catalog # 31000, 
Biotium, Hayward, CA), 0.67 U of Fermentas Hot Start Taq DNA polymerase (catalog # 
EP0603, Thermo Scientific, Wilmington, DE), 3 mM MgCl2 and 0.2 mM each dNTP. 
The cycling parameters were: 95oC for 3 min, followed by 40 cycles of 95oC for 10 sec, 
60oC for 30 sec and 72oC for 30 sec, followed by a melting curve analysis with 
temperature range between 60oC and 95oC with a 0.5oC increment. Primer pair specificity 
was confirmed with a single sharp peak in the melting curve. Reference genes were 
deemed appropriate when they had CV and M values of <0.5 and 1 respectively. The 
geometric mean of three to four reference genes was used to normalize the target gene 
expression [2] using BioRad’s Cfx software. Results are reported as Relative Normalized 
Expression based on the !! Cq calculation. 
 
Bioinformatics 
A MOPAT analysis was performed on the region of interest (-192 to -41bp) 
within the Syt11 5’ UTR to identify predicted transcription factor binding sites [3]. The 
list of possible transcription factors was cross-referenced with microarray data of 
immunopanned mouse RGCs [4] to identify transcription factors known to be expressed 
in RGCs (Figure 5). 
After the negative data was obtained from siRNA knockdown of Deaf1, Sp1, 
Elk1, Hsf1 TFs, an additional bioinformatic analysis was performed on the wild type 
compared to the promoter mutants using TRANSFAC-database with an 80% matching 
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threshold to identify predicted TFs. Specifically, the changes in predicted TFBSs in the 
various binding site mutants compared to the wild type promoter sequence were 
examined to determine more relevant predicted transcription factors. These results are 
displayed in Figure 15. 
 
Small interfering RNA knockdown (siRNA KD) 
Immunopanned RGCs were transfected with NeuroMag (0.1uL) complexed with 
a total of 0.02 pmol (Figures 7 and 8) or 0.01 pmol (Figures 11, 12 and 16) of 
siRNA/well in 96 well plates as described earlier. Non-targeting (scrambled) siRNAs 
were used as a negative control. Table 5 shows the siRNAs used, their origin, product 
numbers and sequences. Pools of the individual siRNAs were used to obtain the data in 
Figures 7, 8, 11 and 16. 
For dual siRNA KD and promoter reporter transfection, pools of siRNA and 
plasmids were complexed to Neuromag separately and then mixed together immediately 
before being added to the wells with RGCs. 
Custom unmodified siRNAs with the 9th to the 11th bases complemented (“C911”) 
[5] for Hsf1 and Hsf2 were ordered from Life Technologies (Silencer siRNA, Ambion, 
Life Technologies, Carlsbad, CA) and transfected into rat RGCs using NeuroMag as 
described above (0.1 pmol) (Figure 13). 
 
Overexpression of transcription factors 
ORFs of human Deaf1 and Hsf1 were obtained from Life Technologies (Carlsbad, 
CA) and inserted into an overexpression, Gateway® ready plasmid containing a chicken 
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beta actin promoter and a rabbit beta-globin poly T terminator (pCAG). A human Sp1 
ORF missing the initial seven amino acids was obtained from Addgene (plasmid # 12098, 
Cambridge, MA, deposited by Robert Tjian). The initial seven amino acids were added 
and the ORF amplified using PCR with the following primers (forward 5’- 
CACCATGAGCGACCAAGATCACTCCATGGATGAAATGACAGCTGTGG -3’ and 
reverse 5’-CCTGATCTCAGAAGCCATTGCCACTG -3’). The full length Sp1 ORF was 
inserted into the pENTR vector and then recombined into the aforementioned Gateway® 
ready pCAG vector as previously described. 
 
Transfection of HEK293 cells 
HEK293T cells were transfected with 0.25 µL / well of and 200 ng of plasmid 
total Lipofectamine 2000 (catalog #11668-019, Life Technologies, Carlsbad, CA) in 96 
well plates. Aliquots of media were taken and assayed and RNA collected at 48 hrs post-
transfection as described for primary cells. 
 
Results 
In order to identify an appropriate model gene to study RGC regulatory 
mechanisms, I first selected a set of seven genes that had already been identified as being 
expressed preferentially in RGCs: neurofilament medium (Nefm), neuritin 1 (Nrn1), 
peripherin 1 (Prph1), semaphorin 6b (Sema6b), solute carrier family 17 (sodium-
dependent inorganic phosphate cotransporter), member 6 (Slc17a6), synuclein gamma 
(Sncg) and synaptotagmin 11 (Syt11) [4, 6-9]. To confirm their degree of preferential 
expression in primary rodent RGCs, I tested their relative levels of expression in isolated 
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RGCs compared to whole retina. Figure 1 shows qPCR measurement of the expression of 
the seven genes in rat RGCs and whole retina. The data illustrate that the genes chosen 
were all expressed in RGCs and that they were enriched in RGCs in the context of the 
retina.   
In order to choose which of these seven genes to concentrate on for more detailed 
analysis, I generated and tested promoter reporter constructs for each of the genes. 
Because many genes contain important regulatory sequences within their 5’-upstream 
500 bp region, I focused on this region initially. I created promoter reporter plasmid 
constructs with the regulatory region of interest upstream of a gene for a secreted 
luciferase (Gaussia, GLuc). Figure 2 shows the luciferase activity of the promoter 
reporters for the initial seven genes in RGCs compared to their activity in dissociated 
whole retinal cells, as well as the ratio of activity between the two cell populations. The 
promoter reporters demonstrated a range of activity in the two cell populations. Most 
(Nrn1, Sema6b, Slc17a6, Sncg and Syt11) showed higher activity in RGCs compared to 
whole retinal cells, though some of them had very low activity in both cell populations. 
The Syt11 promoter reporter showed the highest degree of RGC-specific activity and for 
this reason, it was chosen for further analysis.  
 In order to define the active regulatory elements within the upstream region of the 
Syt11 promoter, I needed to narrow down the important region. To accomplish this goal, I 
created a series of GLuc promoter reporters including a sequentially smaller portion of 
the upstream region (deletion series). The longest construct included a bit more of the 
upstream region that the original construct (-656 to +136 bp instead of -375 to +76 bp).   I 
used a co-transfected CLuc reporter containing the full length Syt11 region (-656 to +136 
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bp) as a transfection control. The analysis (Figure 3) showed that the longer constructs (-
656, -553, -490, -373, -336, -270 and -244 bp) had similar activity to each other. 
However, when the regions between -192 and -101 bp and -101 to -41 bp were deleted, 
the promoter reporter activity dropped in a stepwise fashion to the same level as the 
promoter-less GLuc construct indicating the -41, -20, +11 constructs had no 
transcriptional activity. The -101 to +136 bp construct had an intermediate activity 
between that of the -192 and -41 bp constructs. Similar results were obtained when the 
deletion series was tested in mouse RGCs. 
In order to try to determine what transcription factors might be binding within the 
-192 to -41 bp region, I turned to a bioinformatic analysis. Figure 4 shows the 5’ 
upstream region of Syt11 in the rat genome from the UCSC Genome Browser 
(http://genome.ucsc.edu/). The regions shown to be important from the deletion series 
(from -192 to -101 bp and -100 to -41 bp) are bounded by black rectangles. There are 
several stretches of bases that are conserved across several different species within these 
two regions, suggesting that there may be conserved transcription factor (TF) binding 
sites (BSs) (TFBSs). Figure 5 shows the results of the initial MOPAT bioinformatic 
analysis of the region of interest within the Syt11 promoter (-192 to -41 bp). A number of 
TFs had predicted binding sites BSs between -192 and -41 bp. Both DEAF1 and SP1 had 
a predicted BS between -192 and -101 bp and one between -101 and -41 bp, which if they 
were involved in Syt11 transcriptional regulation, could explain why there was an 
incremental decrease in activity when those regions were excluded. One way to test their 
involvement was to create constructs with these specific TFBSs mutated. For this reason, 
the predicted binding sites for DEAF1 and SP1, alone and in various combinations, were 
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mutated in the full length (-656 to +136 bp) construct by introducing transversions for 
each nucleotide and tested in RGCs. A co-transfected full length, wild type Syt11 (-656 to 
+136) CLuc construct was used as a transfection control. 
Figure 6 shows the activity of the DEAF1 and SP1 binding site mutants in rat 
RGCs. All of the mutant constructs had a greater than 32% decrease in activity compared 
to the unmutated construct. When all four of the sites (both DEAF1s and both SP1s) were 
mutated in the promoter reporter construct, there was a 75% drop in activity and when 
both DEAF1 sites were mutated, there was a 71% drop in activity. These results 
suggested that the sequences including the predicted DEAF1 and to a lesser extent SP1 
binding sites had a positive influence over the promoter-reporter activity. In order to 
specifically test DEAF1 and SP1’s involvement in Syt11 transcriptional regulation, 
siRNA knockdown (KD) of Deaf1 and Sp1 was pursued. 
Figure 7 shows the results of Deaf1 and Sp1 knockdown in RGCs using pools of 
four different unmodified siRNA oligonucleotides (oligos). The pools of oligos were 
specific to their target in the small number of targets measured – in other words Deaf1 
siRNA oligos decreased the level of mRNA of Deaf1 but not Sp1 and the same was true 
of the Sp1 oligos. However, despite a decrease in Deaf1 and/or Sp1 mRNA, there was no 
change in the Syt11 mRNA level. Though there was no change in the endogenous Syt11 
mRNA expression with siRNA KD of Deaf1 and Sp1, I wanted to test whether their KD 
could influence the activity of the Syt11 promoter reporter. When siRNA KD was 
combined with Syt11 promoter reporter transfection (Figure 8), there was a slight 
decrease in reporter activity at later time points when the pool of oligos targeting Deaf1 
was applied, but no change when the pool of oligos targeting Sp1 was applied (Figure 
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8A). The KD of target in the dual transfection was not as efficient as that of siRNA KD 
alone (Figure 8B), so this may have softened the potential decrease in the promoter 
reporter activity. 
Another way to test whether DEAF1 and SP1 TFs influence the transcriptional 
regulation of Syt11 is to over-express them in an immortalized cell line and measure the 
Syt11 promoter reporter activity. Figure 9 shows the effect of Deaf1 and Sp1 over-
expression on the Syt11 promoter reporter activity in HEK293 cells. The over-expression 
of Deaf1 and Sp1 alone or together, did not alter the promoter reporter activity 
significantly compared to empty over-expression vector. 
Because these results did not support an integral part for DEAF1 or SP1 in the 
regulation of the transcription activity within the Syt11 promoter, the expression of 
additional TFs that had predicted BSs based on the original MOPAT analysis was 
examined with qPCR (Figure 10). These results show that most of the TFs measured had 
different expression in brain, retina and RGCs with some being more highly expressed in 
RGCs. Because ELK1, HSF1 and HSF2 all had predicted BSs that overlapped with the 
DEAF1 and SP1 BSs, I chose to use siRNA to knock down their expression. Pools of 
siRNAs targeting Elk1, Hsf1 and Hsf2 were transfected into RGCs using Neuromag. 
These oligo pools knocked down their target (Figure 11) and had varying effects on the 
expression of the other targets and Syt11 measured via qPCR. Elk1 KD did not affect 
Syt11; however, Hsf1 KD decreased the expression of Syt11. Additionally, Hsf2 KD 
decreased the expression of Hsf1 and increased the expression of Syt11. Hsf1 and Hsf2 
KD both increased the expression of Elk1. 
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To confirm the KD of Hsf1 and Hsf2 and the effect on Syt11 expression, the 
oligos were tested in a pool and individually (Figure 12). The pools of Hsf1 and Hsf2 
oligos decreased their target and decreased and increased Syt11 expression respectively 
as before. However, individual oligos did not always decrease their target as efficiently as 
the pool did and those that did decrease their target did not always affect the expression 
of Syt11 as the pool did. For example, the Hsf1-4 oligo decreased Hsf1 expression the 
most, but had very little effect on Syt11 expression. Hsf1-1 and Hsf1-2 both decreased 
Hsf1 expression somewhat, but did not affect Syt11 expression. The Hsf1-3 oligo both 
decreased Hsf1 expression and decreased Syt11 expression as the pool did. The Hsf2-1 
oligo had a similar effect to the Hsf2 oligo pool in that it decreased Hsf2 expression and 
increased Syt11 expression the same amount as the pool.  Similar to Hsf1-4, Hsf2-2 
decreased Hsf2 expression the most, but did not change Syt11 expression. This suggests 
that some of the effects seen might be due to off-target effects. To investigate possible 
off-target effects, custom oligos were synthesized with the 9th, 10th and 11th bases 
complemented (C911 oligos) [5] and tested in RGCs.  
 Figure 13 shows the results of the transfection of rat RGCs with the “wild type” 
and their corresponding C911 siRNAs targeting Hsf1 and Hsf2. The knockdown of the 
targets by the individual wild type siRNAs was slightly different than that in Figure 12, 
but they all decreased their target to varying degrees. Additionally, their effects on Syt11 
were similar to that in Figure 12. The C911 oligos, however did not knock down the 
expression of their targets compared to the wild type siRNAs suggesting the KD of the 
wild type oligos’ targets were all on-target effects. However, with one exception, the 
effect on Syt11 expression did not differ between the wild type and its corresponding 
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C911 siRNA, suggesting that the effects on Syt11 expression were all off-target. The one 
C911 siRNA whose effect on Syt11 differed from that of its corresponding wild type 
siRNA was Hsf2-1 as the wild type siRNA increased the expression of Syt11 but the 
corresponding C911 oligo did not increase Syt11 expression as much. 
As another approach to test HSF1’s influence on Syt11 transcriptional regulation, 
an over-expression analysis was performed in HEK293 cells. Hsf1 over-expression in 
HEK293T cells did not induce endogenous Syt11 expression as measured by qPCR 
(Figure 14A), nor did it increase the Syt11 promoter reporter activity (Figure 14B). These 
results suggested HSF1 was not involved in Syt11 transcriptional regulation. 
 Because none of the previously studied TFs seemed to strongly influence Syt11 
transcriptional regulation, at least when down-regulated in isolation, an additional 
bioinformatic analysis was performed using the Transfac mouse transcription factor 
database. An 80% matching threshold was used to compare predicted TFBSs in the 
DEAF1 and SP1 binding site mutants compared to the wild type construct (Figure 15). 
Some of these additional TFs with predicted BSs within the region of interest were 
knocked down with pools of siRNA oligos (Figure 16). Though some of the siRNA 




Ethanol has been reported to up-regulate Syt1 expression through induction of 
Hsf1 expression in mouse cortical neurons [10]. To test whether this was true for Syt11 
expression in rat RGCs, I treated RGCs with 0, 20, 60 and 180 mM ethanol for 2 hours 
33!
!
and collected RNA at 4, 8 and 24 hours post-treatment and measured gene expression via 
qPCR (Figure S1). Hsf1, Hspa1a and Syt1’s expression increased with time in culture, 
but not in response to ethanol treatment. Syt11 expression did not change over time or in 
relation to ethanol treatment. 
Clozapine and MK801 have been reported to up- and down-regulate Syt11 
expression in brain respectively [11, 12]. To test whether this was true for rat RGCs, I 
treated RGCs with DMSO, 0.4, 2 and 10 uM clozapine and 1.2, 6 and 30 uM MK801 and 
collected RNA after 48 hrs in culture and measured gene expression via qPCR. Neither 
clozapine nor MK801 consistently altered the expression of Syt11 (Figure S2). 
 
Discussion 
The objective of this study was to determine important cis-regulatory elements 
involved in retinal ganglion cell (RGC) gene expression. We performed transient 
transfection of murine primary RGC cultures using promoter reporters that contained the 
5’ upstream 500 bases of seven genes known to be expressed in RGCs.  From an initial 
set of seven genes reported to be enriched in RGCs within the retina, based on its 
preferential activity in RGCs, we chose to concentrate on the Syt11 promoter.  
The results of the initial qPCR comparing the expression of the seven genes in 
RGCs compared to whole retina (Figure 1) were as expected given these genes were 
chosen for reportedly being enriched in RGCs within the context of the retina.  
Most of the promoter reporters of the original seven genes (Nrn1, Sema6b, 
Slc17a6 and Sncg) had overall low activity in both RGCs and whole retinal cells (Figure 
2). This is likely because the promoter reporters did not include the region(s) that 
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conferred robust transcriptional activity or potentially the chromatin context necessary for 
the function of the regulatory region was not maintained when in a plasmid. Several of 
the promoter reporters (Nrn1, Sema6b, Slc17a6, Sncg and Syt11) did have higher activity 
in RGCs compared to whole retina even though several of them had overall low activity. 
The high activity of the Nefm promoter reporter in whole retinal cells compared to RGCs 
was surprising given its low expression in whole retina as measured via qPCR. This high 
level of activity in retina compared to RGCs could be explained by a relatively short 
promoter region that may not have included RGC-specific TFBSs that might be 
inhibitory in other retinal cells; however, this was not investigated further. The Syt11 
promoter reporter had the highest activity in RGCs of all of the promoter reporters and 
also had the highest RGC-specific activity indicating the promoter reporter likely 
included sequence required for its transcriptional promoting activity in RGCs. 
Syt11 belongs to the family of synaptotagmin proteins, which are synaptic 
proteins involved in vesicle release and recycling [13]. To date, sixteen different 
synaptotagmins have been identified in the human genome [14]. Most synaptotagmins are 
calcium sensors and initiate vesicle fusion by interacting with SNARE proteins when 
calcium is present [15]; however, Syt11 and Syt4 both have altered calcium binding 
domains, which precludes their calcium binding abilities [16]. Syt11 has specifically been 
studied in a neuronal context regarding schizophrenia [17] and parkinson’s disease [18]; 
however, it has not been reported to be involved in RGC biology. 
The Syt11 promoter has a sequence with homology to a typical TATA box 
(TATATAAA) located at -381 to -374; however, its position is unusual. According to the 
accepted/published Syt11 transcriptional start site, this likely does not fulfill the role of a 
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traditional TATA box, which would be typically located approximately from -31 to -26 
[19]. It also has what could be considered an Initiator (CCAGTCT) located at -22 to -16, 
but this location is not at the typical -2 to +4 location of true Initiators. The Syt11 
promoter has three possible Downstream Promoter Elements (DPEs) as follows: GGATC 
from +54 to +58 bp, AGTCG from +75 to +79 bp and AGTTG from +150 to +154 bp. 
DPEs are typically found in promoters that lack a TATA box, however they are typically 
located +28 to +32 bp relative to the A+1 nucleotide in the Initiator motif and they 
typically act in concert with an Initiator sequence [19], which the Syt11 promoter does 
not possess. 
The results of the Syt11 promoter deletion series (Figure 3) suggested that the 
region between -192 and -41 bp contained sequences that are important for the promoter 
activity of the promoter reporter and likely contained binding sites for important 
transcription factors. Conservation of promoter sequences across evolution can be helpful 
in defining regulatory elements. However, since there is only limited conservation of the 
region between -192 to -101 bp (UCSC Genome Browser) (Figure 4), this approach was 
not helpful in identifying the regulatory Syt11 elements. 
The initial MOPAT analysis identified DEAF1 and SP1, among others (Figure 5), 
as possible candidate transcription factors important for Syt11 transcriptional regulation, 
which was supported by the binding site mutagenesis in which mutation of any of the 
DEAF1 or SP1 predicted BS sequence decreased the promoter reporter activity (Figure 
6). DEAF1 is a transcription factor whose altered expression has been linked to a number 
of diseases and conditions including depression and suicide [20-22], intellectual disability 
[23], neoplasia [24, 25], neural tube defects [26] and immune disorders [27]; however, 
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nothing has been published about its expression in RGCs. Sp1 is a widely expressed gene 
involved in the transcriptional regulation of many genes [28, 29]. Sp1 has been shown to 
be expressed in RGCs and may play a role in the differential gene regulation in small 
versus large RGCs [30]. SP1’s role in transcriptional regulation of Syt11 has been 
investigated previously in the context of CpG methylation [31]. SP1 and DEAF1, 
together, have been linked in the transcriptional regulation of Gdf5, which is implicated 
in musculoskeletal development [32].  
siRNA KD of Deaf1 and Sp1 alone or in combination did not alter Syt11’s 
expression level (Figure 7). Though the knockdown of Deaf1 slightly decreased the Syt11 
promoter reporter activity (Figure 8), the over-expression of Deaf1 in HEK293 cells only 
marginally increased the Syt11 promoter reporter activity. The most supportive evidence 
of DEAF1 and SP1 playing a role in Syt11’s transcriptional regulation came from the 
mutagenesis assay, which implicated a role for their putative binding sites; however, 
because it is possible that the mutation of the predicted DEAF1 and SP1 binding sites in 
the promoter reporter construct affected important sequences for other transcription factor 
binding, the siRNA KD of additional predicted TFs was pursued. 
TFs that had predicted binding sites that overlapped with the DEAF1 and SP1 
sites that were mutated included HSF1, HSF2, ELK1, GATA1 and ETF (Figure 5). HSF1 
and HSF2 (heat shock factors) are transcription factors involved in the transcriptional 
regulation of heat shock proteins, which are chaperone proteins involved in cellular stress 
responses[33, 34]. Both Hsf1 and Hsf2 are expressed in RGCs and have been implicated 
in the response to various induced cellular stresses [35, 36]. However, in drosophila, 
HSF1 binding sites are more often than not located in genes that are not involved in heat 
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shock response [37]. ELK1 is a member of the ternary complex factor subfamily and is 
involved in the c-fos pathway among others [38-41].  
Knockdown of Hsf1, Hsf2 and Elk1 was successful, however only KD of Hsf1 
and Hsf2 altered the expression of Syt11 (Figure 11). When tested separately, however, 
the individual siRNAs targeting Hsf1 and Hsf2 did not always act as the pool did (Figure 
12). This suggests that off-target effects may have played a role in producing the 
observed effects on Syt11 expression. For this reason, an attempt to tease out the possible 
off-target effects was done by testing the ability of siRNAs for Hsf1 and Hsf2 that had the 
9th, 10th and 11th bases complemented [5] to decrease Syt11’s expression (Figure 13). 
The results of the C911 analysis overall suggest that the knockdown effect of the 
individual wild type siRNAs on their specific target (Hsf1 or Hsf2) were, in fact, on-
target effects because the C911 oligos did not affect their targets as the wild type siRNAs 
did. However, with one exception (Hsf2-1), the effect on Syt11 expression did not differ 
between the wild type and its corresponding C911 siRNA, which overall suggests that the 
effects on Syt11 expression are off-target effects. HSF1 is likely not involved in the 
transcriptional regulation of Syt11 evidenced by the fact that only one of the four siRNA 
oligos decreased its expression when tested individually and the mutated C911 oligos had 
the same effect on Syt11’s expression as the wild type ones did. HSF2’s involvement is 
unclear since only one of the two oligos tested influenced Syt11’s expression and one of 
the C911 oligos did not increase Syt11’s expression to the same degree as its 
corresponding wild type oligo.  
Two other attempts to find supporting evidence that HSF1 influences the 
transcription of Syt11 included over-expression of Hsf1 in HEK293 cells (Figure 14) and 
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ethanol treatment of RGCs (Figure S1). The over-expression of Hsf1 did not cause higher 
activity of the Syt11 promoter reporter, nor did it induce the endogenous expression of 
Hsf1 measured via qPCR in HEK293 cells (Figure 14). Additionally, time in culture but 
not ethanol treatment increased Hsf1 expression, but Syt11 expression was unaffected in 
the experiment by any parameter, suggesting HSF1 is not involved in the transcriptional 
regulation of Syt11.  
Syt11 was reported to be up-regulated in brain with systemic treatment of 
clozapine and down regulated when treated with MK801 [11, 12]. Clozapine at 0.4 and 2 
µM did up-regulate Syt11 compared to both DMSO and untreated and 1.2 µM MK801 
treatment did down-regulate Syt11 expression, but the higher doses either had no effect, 
or increased it compared to the DMSO-treated and untreated RGCs (Figure S2). These 
results could be a reflection of a truncated dosage response curve with some doses having 
the predicted effect. Additionally, these results may reflect similarities between RGCs 
and cortical neurons. 
An additional bioinformatic analysis of the Syt11 promoter region suggested that 
GABPAa and other TFs might be involved in the transcriptional regulation of Syt11 
(Figure 15). However, KD of Gabpa was unsuccessful so its influence on Syt11’s 
expression could not be elucidated. The siRNA KD of the other potentially involved TFs 
(ETS2, JUN and NR2C2), though variably successful, did not influence Syt11 expression, 
suggesting they are not involved in Syt11 transcriptional regulation (Figure 16). 
Though these results are interesting and suggest that the sequence from -192 to -
41 bp contains important sequence for Syt11’s promoter activity, our siRNA experiments 
were inconclusive in identifying the specific TFs that regulate Syt11 transcription in 
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RGCs. It is possible that some of the identified TFs could work in concert to affect 
Syt11’s expression and when examined individually, these effects were not apparent. 
Future studies to further investigate the transcriptional regulation of Syt11 include 
additional bioinformatic analyses to identify potentially involved transcription factors. An 
unbiased scanning mutagenesis assay of the entire region of interest could help to identify 
subregions that convey promoter activity, which would allow a more detailed 
bioinformatic analysis. Use of CRISPR-mediated knockdown of candidate TFs could 
provide another experimental approach that might be more powerful and more specific 
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Nefm Synthesized by 
GenScript 
 -424 to +76 450 
Nrn1 Synthesized by 
GenScript 
 -473 to +76 450 
Prph1 Synthesized by 
GenScript 
 -423 to +27 450 
Sema6b Synthesized by 
GenScript 












Sncg Synthesized by 
GenScript 
 -404 to +45 450 
Syt11 Synthesized by 
GenScript 
 -375 to +76 450 
!
Table 1. Construction of initial seven promoter reporters. Most of the promoter 
reporters were created with synthesized fragments of the promoter region (Nefm, Nrn1, 
Prph1, Sema6b, Sncg, Syt11) and included 450 bases of the upstream region. The 
sequences submitted for synthesis were obtained from the UCSC Genome Browser for 
each of the genes. The promoter reporter for Slc17a6 was created by amplifying a region 
upstream of the Slc17a6 gene from genomic DNA from a Sprague-Dawley rat with PCR 














Forward Primer Reverse primer Region 
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Table 2. Primers used to amplify Syt11 promoter fragments for the creation of the 
deletion series. A series of 12 deletion mutants were created by amplifying progressively 
smaller regions of the promoter series from genomic DNA from a Sprague-Dawley rat. 
Forward primers include CACC- overhang necessary for directional cloning into pENTR. 











































1st half of 2nd 
DEAF1 with 1st 








2nd half of 2nd 
DEAF1 with 1st 








2nd SP1 with 2nd 
DEAF1, 1st SP1 



































2nd SP1 with 2nd 
DEAF1 
 
Table 3. Primers for site directed mutagenesis of Syt11 promoter reporter. 
Transcription factor binding site mutants were created for DEAF1 and SP1 within the 
upstream region of Syt11 using site directed mutagenesis within the full length construct 
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created for the deletion series (-656 to + 136 bp). Because of the length of some the 




Table 4: qPCR primers 
Species & 
Gene 
Forward Primer Reverse Primer 











Rat Nrn1 CGTCATTTGCGAGAATACCA TCTTCACCCTCCAGTAGTTTCC 
Rat Prph1 GCCGGAAGATGGTTCTGAT GCTGCTCCTTCTGAGACTCTGT 
Rat Sema6b GGTCACCCATGGCCTTTT TAGTCCCTGGGAGCCACA 
Rat Slc17a6 GATTCCGGGCGGATACAT TATGGCAGCCCCAAAGAC 




Rat Deaf1 GTGACCCAGGCGAGAATG GCCGCAGTTGACACATGA 








Rat Elk1 CACCAGTCCAAACCCCTTAG TCAACTCTTCAGATTTCTGGTTT
G 
Rat Gabpa GGTTGCCCACATTCCCAAAC TCCTGCCAAACTTGCTCCAT 
Rat Creb GACGGAGGAGCTTGTACCAC GCATCTCCACTCTGCTGGTT 
Rat Ebf1 CAGCTGCCAACTCACCCTA GGGGAGGCTTGTAGATGAGG 




Rat Jun GCCACCGAGACCGTAAAG CTGTGCGAGCTGGTATGAGT 







Rat Rreb1 ACCTCACACGGCACATGA CGCAGGTCTGACACTTGTATG 
Rat Sf1 CGTAAACTGCGCACAGGA GATTGGCTCAGGGGAAGG 
Rat Tcf4 AAAAGTTCCTCCAGGCTTGC TCCCTGTTGTAGTCGGCAGT 
Rat Tp53 AGAGAGCACTGCCCACCA AACATCTCGAAGCGCTCAC 
Rat Zfp384 CCAAGCCCTACAACTGTTCC TTGTATGGTCTATCGCCAGTGT 
Rat Hmga1 TGAAGTGCCAACCCCGAA CTCCTCTTCCTCCTTCTCC 
Rat Nr2c2 CACCTCAGCGCATTCAGA TGCTGTTTAGAGGATCCAGAGG 
Rat Ets2 CACAATCGTTGTGGCTATTTG GTTTGTGTATCCACCACATGCT 
Rat Tcfcp2 GAATCCGGCTCTTCAACG CGTCCTCCTGCTTCTGCT 
Mouse Deaf1 GCCACTGCTGTCATCTCTGA CACACCTGCCTCTTGCACT 
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Mouse Hprt CCTCCTCAGACCGCTTTTT AACCTGGTTCATCATCGCTAA 
Mouse Hmbs TCCCTGAAGGATGTGCCTAC AAGGGTTTTCCCGTTTGC 






















Table 4. qPCR primers. Primers sequences came from RT Primer database 








Company Product Product # Modified or 
unmodified 
Sequence 
Deaf1 Rat Dharmacon siGENOME D09674201 Unmodified GUACAGCCCAA
CCGAGUUU 
Deaf1 Rat Dharmacon siGENOME D09674202 Unmodified GCGAUGACAUG
ACUCUAAG 
Deaf1 Rat Dharmacon siGENOME D09674203 Unmodified AGAAAGGUGGU
ACCAAGUA 
Deaf1 Rat Dharmacon siGENOME D09674204 Unmodified CAGAUAACGUC
UUCACAAC 
Sp1 Rat Dharmacon siGENOME D09001201 Unmodified GCAAGGGUCUG
AUUCUCUA 
Sp1 Rat Dharmacon siGENOME D09001202 Unmodified GAGGAGCGAUC
AUCUGUCA 
Sp1 Rat Dharmacon siGENOME D09001203 Unmodified GAUCAUACCAG
GUGCAAAU 
Sp1 Rat Dharmacon siGENOME D09001204 Unmodified CCAAGGAUGCG
GCAAAGUA 
Deaf1 Mouse Dharmacon siGENOME D04394701 Unmodified GCAGAUAACGU
CUUCACAA 
Deaf1 Mouse Dharmacon siGENOME D04394702 Unmodified CAACUCCAGUG
AAGAAGGA 
Deaf1 Mouse Dharmacon siGENOME D04394703 Unmodified GGCAAACGCAG
CAUCGAUA 
Deaf1 Mouse Dharmacon siGENOME D04394704 Unmodified GGAUAUGGGUA
CCGAGGCU 
Sp1 Mouse Dharmacon siGENOME D04063305 Unmodified GAACAGAGUGG
CAACAGUA 
Sp1 Mouse! Dharmacon siGENOME D04063306 Unmodified GGAUGGUUCUG
GUCAAAUA 
Sp1 Mouse! Dharmacon siGENOME D04063307 Unmodified GAAUAGCUCUG
AUCUCCAA 
Sp1 Mouse! Dharmacon siGENOME D04063308 Unmodified GCAAGGAAGUC
AGCAGAAA 


































Hsf2 Rat Ambion Silencer 62257 Unmodified GGAAAGAGAUG
GCCCUGUUtt 
























Ambion Silencer Custom Unmodified GGAAAGAGTAC
GCCCTGTTtt 
Gabpa Rat Ambion Silencer 61785 Unmodified GGUAAUUUCUU
ACCAAGGAtt 
Gabpa Rat! Ambion Silencer 61700 Unmodified GGAGUGAAAAC
AGAUGGGAtt 
Gabpa Rat! Ambion Silencer 61610 Unmodified GGCCAUAGACA
UCAAUGAAtt 
Gabpa Rat! Ambion Silencer 157638 Unmodified GCAUUGUGGAA
CAAACCUAtt 
Nr2c2 Rat Ambion Silencer 261089 Unmodified GGAGGGAGUAU
CCAUGUCAtt 
Nr2c2 Rat! Ambion Silencer 261088 Unmodified GCGCAUUCAGA
UUGUAACAtt 
Nr2c2 Rat! Ambion Silencer 261087 Unmodified GCUAUAGUUCU
CUUUAGUCtt 
Ets2 Rat Ambion Silencer 70249 Unmodified GGCUCCAUAUG
GAAUGCAGtt 
Tcfcp2 Rat Ambion Silencer 85381 Unmodified GGACAUCUGUG
UUUAUUCAtt 
Tcfcp2 Rat Ambion Silencer 85191 Unmodified GGACAGUCUUA
UGAAAUCCtt 
Jun Rat Ambion Silencer 155944 Unmodified CGAUGGACUUU
UCGUUAACtt 
Jun Rat! Ambion Silencer 67634 Unmodified GGAAAAAGUGA
AAACCUUGtt 
Jun Rat! Ambion Silencer 67730 Unmodified GGGUACACAAG
AUGGACUGtt 
!
Table 5. siRNAs used to knockdown the expression of specific transcripts in mouse 







Figure 1. Expression of original 7 genes in adult and rat pup retina and RGCs. The 
originally chosen seven genes have higher expression in rat RGCs compared to rat whole 
retina and were higher in RGCs from pups than adult RGCs. The seven genes chosen for 
initial promoter analysis were measured via qPCR in immunopanned rat RGCs and 
dissociated whole retinal cells. Expression of target genes was normalized to the 
geometric mean of three reference genes: Gapdh, Hprt1 and Hmbs and then to the Pup 
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Figure 2. Activities of initial promoter reporters. The initial set of promoter reporters 
have different activity in RGCs compared to whole retina. Most promoter reporters have 
higher activity in RGCs, though most have low activity overall. The Nefm promoter 
reporter has higher activity in whole retina compared to RGCs. The Syt11 promoter 
reporter has higher activity in RGCs compared to whole retina. Error bars display the 
standard deviations. Length of constructs: Nefm (-424 to +76 bp), Nrn1 (-473 to +76 bp), 
Prph1 (-423 to +23 bp), Sema6b (-473 to +76 bp), Slc17a6 (-312 to +408 bp), Sncg (-404 



















































Figure 3. Syt11 promoter deletion series. The deletion series demonstrates critical 
sequence between -192 and -41 bp for promoter activity in rat and mouse RGCs. A series 
of deletion mutants of the Syt11 promoter region showed a similar level of activity when     
-656 to -192 bp was included and a step-wise decrease in activity when -192 to -101 bp 
and -100 to -42 bp were excluded. Promoter region from -41 to +11 bp did not confer any 
transcriptional activity. Error bars display the standard deviations. Gaussia luciferase 
values (of the deletion mutant constructs) were normalized to a co-transfected SV40-
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Rat RGCs Mouse RGCs 
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Figure 4. Syt11 upstream region shows areas of sequence conservation. The two 
critical regions identified in the promoter deletion series are outlined in black boxes. 
Areas of conserved sequence suggest areas where important transcription factors might 
bind. This image was taken from the UCSC Genome Browser (http://genome.ucsc.edu/). 
Black vertical arrow indicates the Syt11 transcriptional start site. White arrow indicates 








Figure 5. Predicted transcription factor binding sites (TFBSs) in the region of 
interest (-192 and -41 bp) in the Syt11 upstream region. Predictions are from a 
MOPAT analysis (Hu 2007), which was then cross-referenced to immunopanned mouse 
RGC microarray data to determine which predicted TFBSs were most relevant. Of 
particular interest because of their location within the two sub regions, were the binding 
sites of DEAF1 and SP1. Vertical black arrow indicates ~-101, the boundary between the 
two deletion mutants that had a stepwise drop in activity. This figure prepared in and 
created by Geneious software. 
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Figure 6. Activities of DEAF1 and SP1 binding site mutant promoter reporters. 
Mutation of all sites and DEAF1 sites decreased the Syt11 promoter reporter activity in 
rat RGCs the most. All mutants were significantly lower than the unmutated construct, 
suggesting that all of the mutated sequenced plays a positive role in the transcriptional 
activity of the Syt11 promoter reporter. Gaussia luciferase values (of the binding site 
mutant constructs) were normalized to a co-transfected full length, wild type reporter 





























Figure 7. Knockdown of Deaf1 and Sp1 using siRNA. Greater than 75% knockdown of 
Deaf1 and Sp1 in rat and mouse RGCs did not alter Syt11 expression. Pools of four 
different siRNAs to Deaf1 and Sp1 alone and together decreased the expression of their 
target but did not change Syt11 expression.  Target gene expression was normalized to 
the geometric mean of three reference genes: Gapdh, Hprt1 and Hmbs. Bars represent the 







































































































































































































































Figure 8. Activity of Syt11 promoter reporter with knockdown of Deaf1 and Sp1. 
siRNA KD of Deaf1 but not Sp1 decreased the activity of the Syt11 promoter reporter. A. 
Luciferase data demonstrating that when Deaf1 was knocked down, either alone or in 
combination with Sp1, the promoter reporter activity decreased indicating DEAF1 has a 
positive influence over the Syt11 promoter reporter’s activity. B. qPCR data showing that 
the siRNA KD was not as efficient in this dual plasmid/siRNA transfection experiment. 
Deaf1 expression was decreased by 22% (alone) and 32% (with Sp1) and Sp1 expression 
was decreased by 6% (alone) and 35% (with Deaf1). Syt11 expression was unaffected by 
the siRNA KD of Deaf1 and Sp1. Bars represent the average of technical triplicates of a 
single biological replicate with standard errors of the mean. Target gene expression was 
normalized to the geometric mean of three reference genes: Gapdh, Hprt1 and Hmbs. 





Figure 9. Deaf1 and Sp1 over-expression in HEK293 cells. Deaf1 & Sp1 over-
expression alone or together in HEK293 cells did not significantly alter the activity of the 
Syt11 promoter reporter. An empty over-expression vector was used to standardize the 
amount of plasmid when Deaf1 and Sp1 were over-expressed alone and was used in the 
“no TFs” sample. Gaussia luciferase values (of the Syt11 promoter reporter and Pless-
Gluc) were normalized to a co-transfected full length, wild type Syt11 reporter expressing 
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Figure 10. Expression of different TFs with predicted BSs within the Syt11 upstream 
region of interest (-192 to -42 bp) in RGCs, retina & brain from rat pup. Some TFs 
are more highly expressed in RGCs than in retina or brain. Target gene expression was 
normalized to the geometric mean of three reference genes: Gapdh, Hprt1 and Hmbs. 






















































































Figure 11. siRNA KD of Hsf1 and Hsf2 but not Elk1 altered Syt11 expression in rat 
RGCs. Hsf1 KD of 75% decreased Syt11 expression by 54%. Hsf2 KD of 53% increased 
Hsf1 expression by 49% and increased Syt11 expression by 88%. Elk1 KD of 66% did 
not alter Syt11 expression. Hsf1 and Hsf2 KD both increased Elk1 expression. siRNA KD 
was accomplished with pools of several different oligos for each target. Bars represent 
the average of technical triplicates of biological triplicates with the standard errors of the 
mean. Target gene expression was normalized to the geometric mean of three reference 
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Figure 12. Individual Hsf1 and Hsf2 siRNAs did not always recapitulate the effect of 
the pool of siRNAs. Though all of the individual siRNAs did decrease their target, many 
of them were not as efficient at decreasing the expression of their target or the expression 
of Syt11. Some siRNAs that decreased the expression of their target the best did not alter 
Syt11 expression much if at all (i.e. Hsf1-4 and Hsf2-2). Bars represent the average of 
technical triplicates of biological triplicates. Target gene expression was normalized to 
the geometric mean of three reference genes: Gapdh, Hprt1 and Hmbs. Error bars display 
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Figure 13. siRNA knockdown (KD) of Hsf1 and Hsf2 using “wild type” siRNAs and 
C911 mutant oligos in which the 9th, 10th and 11th bases were complemented [5]. 
Wild type siRNAs decreased their target to varying degrees and C911 mutant siRNAs 
were not as efficient as decreasing their targets suggesting the wild type effects were on-
target. However, only Hsf1-3 decreased Syt11 expression and both the wild type and 
C911 siRNA affected Syt11 equally, suggesting the effect on Syt11 was an off-target 
effect. Bars represent the average of technical triplicates from a single well. An additional 
well was analyzed and had similar results. Target gene expression was normalized to the 
geometric mean of three reference genes: Gapdh, Hprt1 and Hmbs. Error bars display the 































































































Figure 14. Hsf1 overexpression in HEK293 cells did not affect Syt11 promoter 
reporter activity or induce endogenous expression of Syt11. A. qPCR data confirms 
that over-expression was successful but that Syt11 expression remained relatively 
unchanged. Target gene expression was normalized to the geometric mean of three 
reference genes: Gapdh, Hprt1 and Hmbs. Error bars display the standard errors of the 
mean. B. Luciferase data showing that Hsf1 over-expression did not change the Syt11 
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Figure 15. TRANSFAC analysis of Syt11 -192 to -42 bp focusing on the change in 
predictions between the various binding site mutants. Of particular interest is GABPA 
because there are 8 predicted sites in the unmutated construct and only 2 in the All Sites 























































construct compared to the unmutated. Other potentially interesting TFs include HMGA1, 
JUN and PARP1 which have more predicted sites in the All Sites mutated construct 





Figure 16. siRNA knockdown of additional transcription factors predicted to bind 
within the Syt11 promoter region of interest. Though the expression of some of the 
TFs was decreased, there was no difference in Syt11 expression. Bars represent the 
average of technical triplicates of biological triplicates with standard errors of the mean. 
Target gene expression was normalized to the geometric mean of three reference genes: 
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Figure S1. Ethanol treatment of RGCs did not alter Syt11 expression. Hsf1 and Syt1 
expression increased over time in culture, but not due to ethanol treatment. Hspa1a 
expression was slightly increased with ethanol treatment. Lack of change of Syt11 
expression with an increase of Hsf1 expression suggests HSF1 is not involved in the 
transcriptional regulation of Syt11. Bars represent the averages of triplicates of biological 
duplicates. Target gene expression was normalized to the geometric mean of three 
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Figure S2. Clozapine & MK801 treatment of RGCs did not consistently alter Syt11 
expression. Rat RGCs were cultured with clozapine and MK801 and Syt11 expression 
was measured by qPCR after 48 hrs of treatment. Bars represent technical triplicates with 
standard errors of the mean. Target gene expression was normalized to the geometric 
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Identification of the precise regulatory DNA sequences required for photoreceptor 
(PR) specific expression would not only further our knowledge of transcriptional 
regulation and networks in the retina and PRs, but would also allow controlled PR-
directed expression of potential therapeutic molecules within the retina. Additionally, PR-
specific reporters or reporters specific to PR death/survival pathways could be used in 
screens for neuroprotective factors. We and others have been working to define the cis-
acting elements that regulate PR-specific transcriptional activation. Here we describe the 
process by which we have worked to define the regulatory elements that control 
expression of a model PR-expressed gene, S-antigen (Sag). Like the study of Syt11 in 
RGCs, we used primary rodent retinal cells for this study as well, since analyses with 
such cells are more likely to accurately reflect endogenous cell-type specific regulatory 
mechanisms.  
In order to decide which promoter to concentrate on, we performed an initial 
analysis comparing the transcriptional activity of the 5’-upstream regions from sixteen 
genes whose expression pattern had previously been reported to be photoreceptor specific 
within the retina [1, 2]. The set of sixteen genes consisted of opsin 1 medium wavelength 
sensitive (green) cone opsin (Opn1mw), phosphodiesterase 6H (Pde6h), 
phosphodiesterase 6C (Pde6c), guanine nucleotide binding protein, gamma transducing 
activity polypeptide 2 (Gngt2), olfactomedin 1 (Olfm1), solute family carrier 24 
74 
!
(Na/K/Ca exchanger) member 2 (Slc24a2),  rod transducin alpha subunit (Gnat1), 
guanine nucleotide binding protein beta 1 (Gnb1), guanylate cyclase 2d (Gucy2d), retinal 
S-antigen (rod arrestin, Sag), phosphodiesterase 6G (Pde6g), guanine nucleotide binding 
protein gamma transducing activity polypeptide 1 (Gngt1), phosducin (Pdc), retinoschisis 
1 homolog (Rs1), rod outer segment membrane protein 1 (Rom1), ATP binding cassette 
subfamily A member 4 (Abca4) (Table 1). Promoter reporters for each gene were 
constructed using PCR. The promoter reporter for Sag had the highest activity amongst 
the promoter reporters tested, and hence was thus chosen for further analysis. A Sag 
promoter deletion series identified a region of interest (-279 to -182 bp) that when deleted 
led to a significant decrease in promoter activity. Bioinformatic analysis identified 
several candidate transcription factors (TFs) that had predicted binding sites within this 
region of interest. To evaluate the potential role of these candidate transcription factors in 
Sag gene regulation, the expression of several of the TFs was knocked down using 
siRNAs and the consequence of the knockdown on endogenous Sag was assessed. 
 
Materials & Methods 
Primary mouse retinal cells 
All animals were treated in accordance with the ARVO statement for the care and 
use of animals and all procedures were approved by the Johns Hopkins University 
Institutional Animal Care and Use Committee.  
Eyes were removed from mouse pups (postnatal days 1-4 [P1-4]) and retinas were 
isolated from the globes in CO2 independent media (catalog # 18045-088, Life 
Technologies, Carlsbad, CA) containing  2 mM L-glutamine (catalog # 25030-081, Life 
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Technologies, Carlsbad, CA) and 50 U/mL / 50 µg/mL penicillin/streptomycin (catalog # 
15070-063, Life Technologies, Carlsbad, CA). Retinas were rinsed in PBS without Ca2+ 
or Mg2+ (catalog # 10010-023 Life Technologies, Carlsbad, CA) and then digested for 40 
minutes at 37 oC in papain (16.5 U/mL, catalog # LS003119 Worthington, Lakewood, 
NJ) activated in Hibernate-E without Ca2+/Mg2+ (catalog # HE-Ca 500ml, Brainbits, 
Springfield, IL) with 0.2 mg/mL L-cysteine [catalog # C7352 Sigma-Aldrich, St Louis, 
MO] and 250 U/mL DNase I (catalog # D4527, Sigma-Aldrich, St Louis, MO) and pH 
adjusted to 7.4. One mL of activated papain was use per 10 retinas to be dissociated. 
After 40 minutes in papain, the tissue was dissociated into a homogenous single cell 
suspension and the digestion was inhibited with 0.5 mL of a soybean trypsin inhibitor 
solution (15 mg/mL soybean trypsin inhibitor [catalog # LS003587, Worthington, 
Lakewood, NJ], 15 mg/mL bovine serum albumin [BSA] [catalog # 126579, Merck 
KGaA, Darmstadt, Germany] and 125 U/mL DNase I [catalog # D4527, Sigma-Aldrich, 
St Louis, MO] in Hibernate-E [catalog # A12476-01, Life Technologies, Carlsbad, CA]) 
per 1 mL of the cell suspension. The cell suspension was triturated six times with fire 
polished siliconized glass pipettes, then centrifuged for 7 min at 80 x g. Then the 
supernatant was removed and cells resuspended and counted. 
 
Transfection of primary retinal cells 
The dissociated retinal cells were resuspended in electroporation buffer at 
2,000,000 cells/mL (RPMI [catalog # 11875-119, Life Technologies, Carlsbad, CA] with 
10 mM HEPES [catalog # 15630-080, Life Technologies, Carlsbad, CA] and 50 U/mL / 
50 µg/mL penicillin/streptomycin [catalog # 15070-063, Life Technologies, Carlsbad, 
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CA]). Cells were mixed with DNA construct at a final concentration of 0.03 mg/mL and 
DMSO was added to a final concentration of 1.25%. For promoter reporter experiments, 
generally the photoreceptor promoter reporter of interest would be mixed with a plasmid 
containing Cypridina luciferase (CLuc, another secreted luciferase) driven by the 
rhodopsin promoter in a two to one ratio. Expression of CLuc would be used to normalize 
photoreceptor transfection. One hundred uL of the cell/DNA mix would then be loaded 
into the wells of a 96 well electroporation plate (model # HT-P96-2, catalog # 45-0450 
BTX Harvard Apparatus, Holliston, MA). Cells were electroporated with a single square 
pulse of 350 V with 900 µs duration using a BTX Harvard Apparatus HT100 plate 
electroporator (catalog # 45-0400) with an ECM 830 Square Wave Electroporator (model 
# 45-0052, BTX Harvard Apparatus, Holliston, MA).After sitting for 5 minutes at room 
temperature, the 100 uL cell suspension was transferred to a PDL-coated 96 well plate 
containing 100 µL of growth media (Neurobasal [catalog # 21103-049, Life 
Technologies, Carlsbad, CA], B27 supplement [catalog # 17504-044, Life Technologies, 
Carlsbad, CA], 2 mM L-glutamine, 50 U/mL / 50 µg/mL penicillin/streptomycin) per 
well and cultured 37oC with 5% CO2 in a cell culture incubator.  150 µL of media was 
changed after 3-4 hours.  
 
Construction of promoter reporters 
Genomic mouse DNA was isolated from the liver of a C57Bl/6 mouse using the 
QIAmp DNA Mini Kit (catalog # 51304, Qiagen, Germantown, MD). For each construct, 
primers designed to target 500-1000 bases of the upstream promoter region of the genes 
of interest (Table 2) or for specific regions within the Sag promoter region (Table 3), 
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were used to amplify these sequences using PCR, which were then cloned into pENTR 
(catalog # K2400-20, Life Technologies, Carlsbad, CA) by TOPO cloning. The insert 
was then recombined into a Gaussia luciferase (GLuc) promoter reporter Gateway® 
destination vector (pGLuc) using LR Clonase II from Life Technologies (catalog # 
11791-019). Insertion and proper orientation in entry and destination vectors were 
determined by colony PCR with a forward primer within the vector upstream of the 
recombination site and a reverse primer within the insert and final constructs sequenced.  
As mentioned above, for a photoreceptor transfection normalization control, we 
used a rhodopsin promoter-driven CLuc. This construct was made by amplifying a 
sequence 225 base pairs upstream from the transcriptional start site (TSS) to 70 base pairs 
downstream of the TSS (bRho225, from -225 to +70 bp) from a previously created 
bRho225-GLuc reporter construct and using the same cloning strategy described above, 
introduced this sequence into a pENTR plasmid and finally into a CLuc destination 
vector (New England BIolabs, Ipswich, MA). Similarly, as a transfection control for the 
Sag mutations created in GLuc, a “full length” Sag promoter reporter (Sag-429 to +71 
bp) was constructed in the CLuc vector. 
Scanning mutagenesis was done in the -429 to +71 bp Sag promoter construct in 
the pENTR vector using Life Technologies’ Geneart® mutagenesis system by 
introducing transversions for each nucleotide in 10 to 11 bp stretches from -279 to -158 
bp (Table 4). As described above, after sequence confirmation these mutations were 
introduced into the GLuc reporter construct. 
Plasmids were isolated using Promega’s PureYield Midiprep system (catalog # 
A2492, Madison, WI) or Life Technologies’ HiPure Plasmid Filter Maxipreps (catalog # 
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K2100, Carlsbad, CA) and resuspended and stored in TE buffer (10mM Tris-HCl, 1mM 
EDTA, pH 8.0). 
 
Promoter reporter assay 
GLuc promoter reporter plasmids were co-transfected with the bRho225-CLuc 
plasmid into dissociated retinal cells (Figure 1) as described above. Expression of CLuc 
was used to normalize for variation in photoreceptor transfection efficiency. For the Sag 
promoter mutations created in the GLuc vector, we used the -429 to +71 bp Sag CLuc 
construct for normalization (Figures 2 and 4 respectively).  
To assay promoter activity, two 20 uL aliquots of culture media were collected 
seven days after cells were electroporated and luciferase activity was measured using the 
Gaussia and Cypridina luciferase assay kits (separately) from New England Biolabs 
(Ipswich, MA). The GLuc activity was normalized to the CLuc activity within the same 
well by dividing the measured relative light units (RLU) in the GLuc assay by the RLU in 
the CLuc assay as a means to control for transfection efficiency. Empty vectors ([pCLuc-
Basic 2, catalog # N0317S] and promoterless-GLuc [pless-GLuc, pGLuc-Basic 2, catalog 
# N8082S], New England Biolabs, Ipswich, MA) were used as negative controls and 
promoter activity values were expressed as fold change over the GLuc/CLuc RLU values 
measured in these controls. 
 
Small interfering RNA knockdown (siRNA KD) 
siRNAs targeting various transcription factors (Table 5) with predicted binding 
sites in the Sag promoter region were transfected into dissociated retinal cells. siRNAs 
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were pooled and 12 pmol/96 well reaction  were complexed with TrueFect-Lipo (catalog 
# TF1101-2, United Biosystems, Herndon, VA) for 30 minutes in Optimem (catalog # 
31985-070, Life Technologies, Carlsbad, CA) in PDL-coated 96 well plates. Retinal cells 
suspended in growth media (50,000 cells/100 uL) were added to the wells with 
complexed siRNA and cultured. After 48 hours, RNA was collected from each well using 
Qiagen’s Micro RNeasy kit (catalog # 74004) and then all of the RNA collected was 
converted to cDNA using the Applied Biosystems High Capacity Reverse Transcription 
kit. 
 
Quantitative Real Time-PCR (qPCR) 
Sequences of the primers used in qPCR assays are listed in Table 6. Primer 
sequences were chosen through the RT Primer database 
(http://medgen.ugent.be/rtprimerdb/) or designed with Roche’s primer design algorithm 
(http://lifescience.roche.com/shop/CategoryDisplay?catalogId=10001&tab=Assay+Desig
n+Center&identifier=Universal+Probe+Library&langId=-1#tab-3). Primer pair 
efficiencies were determined using a standard curve of cDNA from whole retina and 
deemed adequate if they were between 90 and 110%.  Samples were run in triplicate in a 
BioRad Cfx C1000 384 qPCR machine in a total reaction volume of 8uL; 0.2 uL cDNA, 
125 nM of each primer, EvaGreen (catalog # 31000, Biotium, Hayward, CA), 0.67 U of 
Fermentas Hot Start Taq DNA polymerase (catalog # EP0603, Thermo Scientific, 
Wilmington, DE), 3 mM MgCl2 and 0.2 mM each dNTP. The cycling parameters were: 
95oC for 3 min, followed by 40 cycles of 95oC for 10 sec, 60oC for 30 sec and 72oC for 
30 sec, followed by a melting curve analysis with temperature range between 60oC and 
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95oC with a 0.5oC increment. Primer pair specificity was suggested by a single sharp 
peak in the melting curve. Expression of a single reference gene (beta-actin) was used to 
normalize the target gene expression and results were reported as Relative Normalized 
Expression based on the !! Cq calculation performed by the Cfx software. 
 
Bioinformatics 
A motif pair tree (MOPAT) analysis was performed on the region of interest       
(-279 to -182 bp) within the Sag 5’ UTR to identify cis-regulatory modules (CRMs) that 
may be binding sites [3] of known mammalian transcription factors (Figure 3). 
We also compared the potential transcription factor (TF) binding sites (BSs) in the 
wild type Sag 5’ UTR to the sequences generated by the scanning mutagenesis. Using the 
TRANSFAC-database with an 80% matching threshold to identify TFs with predicted 
BSs (Figure 6), we identified a set of mouse TFs that potentially interact with these 
sequences. 
Statistical Tests 




With the goal of discovering novel cis-regulatory elements and trans-acting 
factors involved in photoreceptor gene regulation, we evaluated published studies on PR 
expression studies to assemble a set of genes on which to focus. Since in most cases the 
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major DNA elements regulating promoter activity are located in the 5! 500-1000 
upstream bases of a given gene [4-7], we cloned the 500-1000 upstream regions of the 
genes to be evaluated into a set of promoter reporter constructs. As we are interested in 
regulatory elements in the context of the photoreceptor rather than assessing expression 
of the reporters in a cell line, we transfected primary murine retinal cultures, which are 
made up of approximately 50-60% rod photoreceptor cells. Retinal cultures were co-
transfected with the CLuc containing reporter constructs for each of the candidate genes, 
and the resulting GLuc activity values of the promoter constructs were normalized to the 
CLuc construct. 
An initial set of promoter reporters was constructed and tested in dissociated 
whole retina cell cultures (Figure 1). Normalized luciferase activity (Figure 1) showed 
that whereas the promoter activity of the -225 to +70 bp upstream bovine rhodopsin gene 
construct was nearly 6-fold higher than that of the pless-GLuc reporter, the majority of 
the promoter reporters showed activity that was approximately two-fold or lower 
compared to the pless-GLuc reporter.  This result indicated the majority of the upstream 
fragments tested had only modest promoter activity in our cell culture system. However, 
the Pdc and Pde6c constructs demonstrated activity that was almost as strong as the 
bRho225-GLuc construct, and both the longer (-859 to +71 bp) and shorter (-494 to +71 
bp) Sag constructs showed activity that was higher than that of the bRho225-GLuc 
construct. Based on these results, the upstream promoter region of Sag was chosen for 
further analysis.  
We next dissected the -859 to +71 bp region of Sag to define the important the 
biologically active regulatory sequences within this region. This was accomplished by 
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performing a deletion series, creating a series of GLuc promoter reporters with a 
sequentially smaller portion of the upstream region. The GLuc activity of these constructs 
were normalized to the activity of a co-transfected CLuc full length Sag (-859 to +71 bp) 
promoter construct.  
Figure 2 shows the normalized luciferase activity of the Sag promoter series of 
deletion mutants. The five longest constructs, -859, -494, -429, -340 and -279 to +71 bp, 
all had similar luciferase activities (between eight and 12 times higher than the promoter-
less GLuc [pless-GLuc] construct). Then there was a sharp, and statistically significant (P 
= 0.0145), decrease in activity from the -181 to +71 bp construct, and smaller decreases 
in the activity from the shortest two constructs (-138 and -37 to +71 bp), neither of which 
had activity that was statistically different from the pless-GLuc construct (P >0.05). 
These results suggest that the region between -279 and -182 bp contained sequences 
important for the activity of the Sag promoter. 
In order to try to determine what transcription factors might be binding within the 
-279 to -182 bp region, I turned to bioinformatic analysis. Figure 3 shows the 
transcription factor binding sites within the -279 to -182 bp sequence that are predicted 
by the bioinformatic tool MOPAT. Several of these predicted TFs, including COUP1, 
COUP2, PPARA and RORA, have been studied in the context of the eye [8-10] and were 
therefore thought to be likely candidate TFs involved in Sag transcriptional regulation. 
siRNA KD of these four TFs was attempted. Figure 4 shows the level of Sag expression 
after transfection with siRNAs targeting Coup1, Coup2, Ppara and Rora. There was 
greater than 40% knockdown of Coup1, Coup2 and Ppara. The siRNA KD of Rora was 
unsuccessful. However, regardless of whether or not the siRNA KD of the TF was 
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successful, Sag expression was increased 1.5 to 2.5 times compared to the non-targeting 
control siRNA. 
In addition to the siRNA KD, an additional analysis of Sag’s promoter region of 
interest was undertaken. An unbiased mutagenesis approach was taken to identify 
important sub-regions within the 97 bp region of interest. Transversions were introduced 
for each nucleotide in 10 bp stretches within this region of interest and construct activity 
was tested using the dissociated retinal cell assay (Figure 5). The GLuc activity of the 
mutant constructs was once again normalized to the CLuc activity of a wild type 
construct (Sag, -429 to +71 bp). Some of the mutants had higher activity than the wild 
type construct, some had similar activity and some had lower activity. Mutants with 
similar activity included -269 to -260 bp and -239 to -230 bp. Those with higher activity 
included -279 to -270 bp, -259 to -250 bp, -249 to -240 bp and -199 to -190 bp. The 
construct with -199 to -190 bp mutated had the highest activity overall and was 
approximately three times as high as the wild type construct. Those with decreased 
activity included -229 to -220 bp, -219 to -210 bp, -209 to -200 bp, -189 to -180 bp, -179 
to -170 bp and -169 to -158 bp. The constructs with -219 to -210 bp, -209 to -210 bp, -
189 to -180 bp, -179 to -170 bp and -169 to -160 bp mutated had the lowest activity, 
approximately half the activity of the wild type construct. The lower activities of some of 
the mutants suggest their region contains binding sites for transcription promoting 
factors. 
Because of the variable activities of the scanning mutagenesis constructs, an 
additional bioinformatic analysis using the TRANSFAC database was performed to 
identify binding sites that were added or removed with the various mutations (Figure 6). 
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This bioinformatic prediction identified a number of transcription factors that might be 




The objective of this study was to identify and characterize important cis-
regulatory elements involved in photoreceptor (PR) gene expression. We performed 
transient transfection of murine primary retinal cultures using promoter reporters that 
contained the 5’ upstream 500-1000 bases of 16 genes known to be expressed in PRs.  
Most of the regulatory sequences tested had marginal promoter activity suggesting that 
either the complete region necessary for promoting robust PR gene expression was not 
contained in the sequences used to create the reporter or potentially that the transfected 
promoter sequences require aspects of chromatin structure that are not present in 
transfected plasmids.  
Additionally, some of the regulatory sequences tested in the study lie in the 
promoter region of cone specific genes (Opn1mw, Pde6h, Pde6c, Gngt2, Olfm1 and 
Slc24a2), and since cones make up only a small percentage of the mixed retinal cultures 
used for this study (approximately 1-2%), even promoter fragments that are active in 
cones, if they are cone-specific, would be expected to show minimal activity compared to 
background when tested in whole retina cultures. Interestingly though, the Pde6c reporter 
containing 763 upstream bases had 2.75 times more activity than the construct containing 
443 bases, suggesting that the sequences necessary for transcriptional activity lie within 
the additional 320 bases contained in the longer construct. Since the activity of this 
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putatively cone-specific promoter is relatively robust in our assay, it is not clear whether 
the sequence being assessed maintains all the elements necessary to restrict its activity 
solely to cone cells. The assay, since it is population-based, does not distinguish between 
a small percentage of cells having a very high expression level (as would be the case if 
the construct maintained cone-specificity) or a large percentage of cells expressing the 
reporter at a moderate level, which may suggest that the sequence we are examining may 
not maintain cone-specific regulatory elements. Further studies in which reporters can be 
analyzed at the cell level, and potentially multiplexed with cone-specific markers, will 
allow us to distinguish between these possibilities and hone in on cone-specific 
regulatory elements. 
The regulatory element that had the highest expression in our assay was the -429 
to +71 bp Sag fragment. The expression of this reporter was 1.22 times higher than our 
rhodopsin promoter construct. Rhodopsin is expressed at a very high level in PRs, and if 
the bRho225 promoter reporter accurately reflects the level of rhodopsin expression in 
these cultures, then the fact that the Sag promoter reporter has higher activity than the 
rhodopsin promoter reporter could be explained several different ways. It is possible that 
Sag is more highly expressed than rhodopsin either in general, or at this stage of 
development. Another possibility is that the promoter reporter included transcription-
promoting sequence but lacked transcription-inhibiting sequence. Last but not least, 1.22 
times greater than rhodopsin is possibly within the realm of random variation in the assay 
and may not reflect a true difference in activity between the two genes’ promoter 
reporters. Because the Sag promoter reporter had the highest activity of all of the 16 PR 
genes of interest, it was chosen for further analysis. 
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 Both of the Sag constructs had similar activity even though one contained 365 bp 
more of the promoter region. This would indicate that the sequence between -859 and      
-494 bp did not contain binding sites for transcription factors important to the promoter 
reporter’s activity, at least in our in vitro assay system.  
The next step in evaluating the Sag promoter region was to make a deletion series. 
The results of the deletion series indicated the region between -279 and -182 bp likely 
contains binding sites for transcription factors that are important for positively regulating 
Sag promoter activity. The initial bioinformatic analysis (MOPAT analysis, [3]) predicted 
that a number of transcription factors had binding sites within this region, several of 
which have been studied within the context of the retina including COUP, RORA, 
PPARA, MEF2, AP2G and TBX5 [8-14]. Of initial interest were the COUP transcription 
factor binding sites because the COUP TFs are involved in eye and specifically retinal 
development [9]. RORA, which also has a predicted binding site within this region, is 
also known to be involved in photoreceptor gene regulation, though primarily in cones [8, 
11]. PPARA is expressed in the retina and exerts protective effects in retinal ischemia 
and in diabetic retinopathy [10, 15]. The siRNA KD of these four transcription factors 
within whole retinal cells was then pursued. 
To explore whether these candidate TFs were indeed positive regulators of Sag 
expression, we attempted to knock down their expression using siRNA technology. 
siRNA knockdown in dissociated retinal cultures is difficult and the technique is still not 
optimized. TrueFect-Lipo transfection reagent, used in this study, is one of the reagents 
shown to have some efficacy in transfecting retinal cells with siRNAs (Zack lab, 
unpublished data). siRNAs targeting Coup1, Coup2, Ppara and Rora were transfected 
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into dissociated retinal cells and then knockdown was evaluated by qPCR. Knockdown of 
Coup1, Coup2 and Ppara was somewhat successful; however, the Rora knockdown did 
not work. Interestingly the Sag expression was not decreased by the knockdowns, but 
instead all of the targeting siRNAs (even the ones that targeted but did not affect Rora 
expression) increased Sag expression. Given the high reported rate of off-target effects of 
siRNAs [16], it is somewhat likely that the effect on Sag expression in this experiment 
may be due to these undesired off-target effects either directly, or through the change in 
expression of the target genes themselves. One way to investigate this possibility is to test 
each siRNA oligo individually and see if, as individuals, they are able to recapitulate the 
effects of the pool [16]. Another way to investigate this further would be to mutate the 
seed sequence, which should decrease on-target but not off-target effects [17]. Overall, 
our siRNA experiments did not implicate any of the identified candidate TFs as being 
important positive regulators of Sag expression. 
As a complementary approach to further define the regulatory regions identified 
by our deletion analysis, we performed a scanning mutagenesis study to identify at a 
higher resolution regulatory sequences within the Sag -279 to -182 bp region of interest. 
The various mutants showed a range of activities compared to the unmutated construct. 
Those that had similar activity indicate that the mutated stretch of bases is not likely to 
play a role in the promoter’s activity. Those with increased activity (-279 to -270 bp, -259 
to -250 bp, -249 to -240 bp and -199 to -190 bp) may indicate a region where an 
inhibitory transcription factor binds, or they may have created a new binding site for a 
transcription-promoting factor. Those with decreased activity (-229 to -220 bp, -219 to    
-210 bp, -209 to -200 bp, -189 to -180 bp, -179 to -170 bp and -169 to -158 bp) may have 
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disrupted a binding site of a transcription-promoting factor or created a binding site of an 
inhibitory factor. According to the initial MOPAT analysis, the mutants that had the 
lowest activity overlapped with the binding sites for PPAR, COUP, RORA, MEF2, and 
TBP. siRNA KD results did not strongly support the involvement of COUP or PPAR, 
leaving MEF2 and TBP as potentially interesting TFs to investigate in the future. 
The additional bioinformatic analysis of the region of interest in the context of the 
scanning mutagenesis suggested a number of additional transcription factors that might 
play a role in Sag transcriptional regulation. TFs with a decreased number of predicted 
sites within mutants with lower activity included HMGA1, PARP1, RARA, SAFB1, SF1 
and TBP. HMGA1 is a potentially interesting transcription factor as it is highly expressed 
in adult mouse photoreceptors and influences the expression of rhodopsin, another gene 
that is highly expressed in rod photoreceptors [18]. Another potentially generally 
interesting transcription factor is TBP. Though there appears to be a TATA box in the 
region of interest within the Sag promoter, it is further away from the transcriptional start 
site than TATA boxes are generally considered to be located [19]. The construct with the 
highest activity is potentially due to the creation of a NEUROD1 binding site. 
NEUROD1 is known to be involved in photoreceptor maturation and development [20] 
and it is possible though unconfirmed that in creating a NEUROD1 binding site, the 
mutant promoter reporter gained increased activity. 
In summary, the 5’-upstream region of a number of photoreceptor-specific genes 
were analyzed for promoter activity in primary retinal cell cultures, and several of them 
were found to have detectable promoter activity. Further investigation of Sag’s 5’-
upstream region defined a 97-bp region that was important for Sag’s promoter activity. , 
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Bioinformatic analysis of this region and siRNA KD of candidate TFs were pursued. 
Though the exact trans-acting factors influencing Sag expression in the retina were not 
identified in this study, a number of potentially involved transcription factors were 
identified. Future work will hopefully define the putative role of these factors in 
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Gene Cell type Name 
Opn1mw* Cone Opsin 1, medium wavelength sensitive (green) cone opsin 
Pde6h* Cone Phosphodiesterase 6H, cGMP-specific 
Pde6c* Cone Phosphodiesterase 6C, cGMP specific 
Gngt2 Cone Guanine nucleotide binding protein, gamma transducing activity 
polypeptide 2 
Olfm1 Cone Olfactomedin 1 
Slc24a2 Cone Solute family carrier 24 (Na/K/Ca exchanger) member 2 
Gnat1* Rod Rod transducin alpha subunit 
Gnb1 Rod Guanine nucleotide binding protein, beta 1 
Gucy2d* Rod Guanylate cyclase 2d 
Sag* Both Retinal S-antigen (rod arrestin) 
Pde6g* Both Phosphodiesterase 6G, cGMP-specific 
Gngt1 Both Guanine nucleotide binding protein, gamma transducing activity 
polypeptide 1 
Pdc  Both Phosducin 
Rs1* Both Retinoschisis 1 homolog 
Rom1* Both Rod outer segment membrane protein 1 
Abca4* Both ATP binding cassette, subfamily A, member 4 
!
Table 1. Initial set of photoreceptor-specific genes chosen to examine. Asterisks 
indicate genes in which disease causing mutations have been found for various human 






































































































































Table 2. Primers for initial promoter reporter construction. A series of promoter 
reporters were created by amplifying upstream regions of genes from genomic DNA from 
a C57Bl/6 mouse. Forward primers include CACC- overhang necessary for directional 
cloning into pENTR. Promoter reporters of two different lengths were constructed for 

























Forward Primer Reverse Primer Region 
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-429 to    
+ 71 
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+ 71 
 
Table 3. PCR primers for Sag deletion series construction. A series of 6 deletion 
mutants were created by amplifying progressively smaller regions of the promoter series 
from genomic DNA from a C57Bl/6 mouse. Forward primers include CACC- overhang 
























































-189 to -180 
 
Table 4. PCR primers for scanning mutagenesis of Sag promoter -279 to -158 bp. A 
series of mutants were made using site directed mutagenesis within the full length 
construct created for the deletion series (-429 to + 71). Ten to 11 bases were mutated at a 









RNA Oligo Sequence 
























Coup1 Ambion Silencer 66695 Unmodified GGCCAGUAUGCACUCA
CAAtt 
Coup1 Ambion Silencer 66605 Unmodified GGAACUUAACUUACAC
AUGtt 
Coup1 Ambion Silencer 66781 Unmodified GGACCAUGAGAAAUUU
AAUtt 
Coup2 Ambion Silencer 65809 Unmodified GGAAAAGUCCCAGUGU
GCUtt 
Coup2 Ambion Silencer 282808 Unmodified GGCAAAAGACUGGUUU
UGUtt 
Coup2 Ambion Silencer 282809 Unmodified GCUUGCAGGAAAAGUC
CCAtt 
Ppara Ambion Silencer 151210 Unmodified CGACCUGAAAGAUUCG
GAAtt 
Ppara Ambion Silencer 151211 Unmodified GGCUAAUAGGAUUCAG
ACAtt 
Rora Ambion Silencer 151977 Unmodified GGUGGUGUUUAUUAGG
AUGtt 
Rora Ambion Silencer 151978 Unmodified GCCAUGCAAAUCGAUG
GGUtt 
Rora Ambion Silencer 71274 Unmodified GGUAUCUCAGUCACGA
AGAtt 
 
Table 5. siRNAs used to knockdown transcription factors in primary mouse retinal 








Coup1 CCTCAAAGCCATCGTGCTATTCAC GATTTCTCCTGCAGGCTTTCGATG 
Coup2 ACTCTTCCAAAGCACACTGGGACT TCCAAGAGCAAGTGGAGAAGCTCA 
Ppara ATGCCAGTACTGCCGTTTTC GGCCTTGACCTTGTTCATGT 
Rora GTGGAGACAAATCGTCAGGAAT TGGTCCGATCAATCAAACAGTTC 
Sag TGAAGCCTCCTGGCAGTTCTTCAT CACAACCTTGTCGGTGTTGTTGGT 
 
Table 6. qPCR primers. All primers were designed to amplify mouse sequence. Primers 
sequences came from RT Primer database (http://medgen.ugent.be/rtprimerdb/) or 







Figure 1. Normalized luciferase activity of photoreceptor gene promoter reporters 
in whole retinal cells. Data demonstrate that both Sag promoter reporters have the 
highest activity. Numbers indicate 5’ upstream region that was included in relation to the 
transcriptional start site (TSS = +1). Luciferase activity was assayed in aliquots of media 
taken seven days post-electroporation. Promoter reporters expressed Gaussia luciferase, 
which was normalized to a co-transfected bovine rhodopsin promoter reporter expressing 
Cypridina luciferase (bRho225-Cluc). Bars represent the averages (with standard 































Figure 2. Sag deletion series. Data demonstrate the normalized luciferase activity of a 
series of deletion mutants of the S-antigen promoter region in dissociated early post-natal 
mouse whole retinal cells. Aliquots of media were taken at seven days post-
electroporation and assayed for luciferase activity. The activity of the Gaussia luciferase 
expressed by the deletion mutants was normalized to a co-transfected Cypridina 
luciferase expressing full length Sag promoter reporter and then normalized to a 
promoterless-Gaussia luciferase construct (Pless-Gluc). The activity of the deletion 
mutants dropped significantly when -278 to -182 (and beyond) was not included. Bars 











































Figure 3. Predicted transcription factor binding sites within the region of interest    
(-279 to -180 bp) within the Sag promoter according to a MOPAT analysis. The 





Figure 4. siRNA KD of Ppara, Rora, Coup1 and Coup2 did not decrease Sag 
expression in dissociated mouse retinal cells. siRNA KD was accomplished with pools 
of several different oligos for each target and was successful at decreasing the expression 
of Ppara, Coup1 and Coup2. Bars represent the average of technical triplicates from 
pools of biological triplicates with the standard errors of the mean. Target gene 







































































































































Figure 5. Scanning mutagenesis of the Sag region of interest (-279 to -180 bp). Data 
demonstrate the normalized luciferase activity of Sag promoter mutants created by 
scanning mutagenesis of 10 bp stretches within the area of interest (-279 to -180 bp), 
which was identified in the deletion series. Transversions were introduced into each 
nucleotide position within the 10 bp region. Some mutations were activating and some 
were repressing compared to the unmutated construct. The bars represent the average of 






























Figure 6. Predicted binding sites of transcription factors in the various binding site 
mutants from a TRANSFAC analysis. Specifically, this analysis examines the change 
106 
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Retinal degeneration (RD) encompasses a group of genetically and clinically 
heterogeneous disorders that primarily affect photoreceptor (PR) and/or retinal pigment 
epithelial (RPE) cells and lead to progressive vision loss. The age of clinical onset and 
degree of disease severity varies significantly, ranging from severe symptoms at birth to 
only mild symptoms in the sixth and seventh decades of life. Two major types of RD are 
Leber congenital amaurosis (LCA), in which infants can demonstrate profound vision 
loss, and retinitis pigmentosa (RP), which is generally not clinically evident until later in 
childhood or in early adulthood. To date, 212 genes have been identified as having 
causative mutations in the various forms of RD with 40 additional loci being linked to 
RD (https://sph.uth.edu/RetNet/). LCA and RP are orphan diseases, affecting 1 in 81,000 
and 1 in 4,000 individuals, respectively [1, 2]. In general, with a few exceptions, the RDs 
are untreatable.  
Age-related macular degeneration (AMD) and diabetic retinopathy are two other 
important diseases that affect photoreceptors. Both diseases have an increased prevalence 
in older adults compared to the general population [3]. Much of the resulting vision loss 
in these two diseases is due to abnormal vascular growth. While there are treatments to 
slow and even reverse the abnormal vessel growth, including most importantly anti-
VEGF therapy, no specific treatment exists to support the photoreceptors. 
Vision loss and blindness from the aforementioned diseases is ultimately a result 
of dysfunction and death of retinal PRs, which are the cells responsible for the 
remarkable conversion of light energy into an electrochemical signal (recently reviewed 




pathway with many components is responsible for this light to electrochemical energy 
conversion. Mutations in many of the genes encoding components of this pathway have 
been implicated in RP and LCA. RPE cells are involved in the recycling of the vitamin A 
derivative, retinal, and its shuttling back to the photoreceptors (the visual cycle); thus, 
mutations in genes encoding important RPE proteins can also cause RD.  
Though the vision-threatening end result of the RDs and other non-specific retinal 
degenerative diseases is all the same (death of PRs), there is much debate over the exact 
mechanisms leading to PR death. A number of different and often opposing mechanisms 
for photoreceptor cell death in retinal degenerative diseases have been proposed and 
studied. One of the challenges in this field is that there are a large number of diverse 
diseases, caused by mutations in an even larger number of genes that affect 
photoreceptors that are modeled by a large number of different animal models. Therefore, 
findings of one model can rarely be generalized to all forms of retinal degeneration and 
there are often very different findings in the various models suggesting very different 
mechanisms of cell death. Initial morphologic studies into photoreceptor cell death in 
retinal degenerations concluded that apoptosis was the final common pathway causing 
cell death [5]. Since then, photoreceptor death in retinal degenerative diseases has been 
further studied molecularly and a number of distinct apoptotic and non-apoptotic 
mechanisms have been identified (reviewed by Sancho-Pelluz et al [6] and Marigo [7]). 
One of the pathways leading to photoreceptor apoptosis is endoplasmic reticulum stress 
and the unfolded protein response (UPR) (reviewed by Jing et al [8] and Wang [9]). 
Parthanatos, in which an over-activation of poly-ADP ribose polymerase (PARP) leads to 




The vast majority of the RDs are untreatable, though advances in various 
treatment modalities have recently made successful therapy a possibility. Gene therapy 
has made the most recent progress in improving vision [11]. Several canine and human 
gene therapy trials have been completed or are underway to treat LCA due to mutations 
in Rpe65, a gene expressed in RPE cells, and they have shown encouraging results [12-
14]. However, since gene therapy is generally designed to target a specific mutated gene, 
most existing and planned gene therapy approaches for the RDs will only be useful for a 
small number of patients.  
Other potential treatments for RD patients include the use of trophic factors and 
small molecules as neuroprotective agents directed at increasing PR cell survival. For 
example, both brain-derived and ciliary neurotropic factors (BDNF & CNTF) have been 
shown to support photoreceptors in retinal degeneration models [15, 16], and CNTF has 
been tested in human clinical trials and has shown some possible success [17]. One 
example of a small molecule showing suggestive efficacy is rasagiline treatment in a 
mouse model of RD, which was shown to delay outer nuclear layer (photoreceptor cell 
bodies) degeneration [18]. In an effort to further develop small molecule-based 
neuroprotective therapies for the RDs, I have been testing protein kinase inhibitors and 
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Chapter 1: Exploration of the ability of protein kinase inhibitors to promote 
photoreceptor survival in murine models of retinal degeneration 
 
Introduction 
Previous work in the Zack lab using phenotypic screens of primary rodent retinal 
ganglion cells (RGCs) to identify neuroprotective compounds identified a number of 
promising small molecules. One of the identified molecules, sunitinib, is a multiple 
protein kinase inhibitor that is an FDA approved cancer chemotherapeutic agent. 
Sunitinib has been shown to promote RGC survival both in vitro and in rodent optic 
nerve injury and glaucoma models (Zhiyong Yang, unpublished data).  
Although sunitinib had very clear RGC survival promoting effects, it was 
unknown which of the many kinases it inhibits accounted for its neuroprotective activity. 
A study by Welsbie et al. using a kinome-wide small interfering RNAs (siRNAs) screen 
with primary mouse RGCs identified DLK (MAP3K12) as an important mediator of 
RGC death [1]. The c-Jun N-terminal kinase (JNK) has been shown to be involved in the 
death of RGCs in several studies [2-5], and there is evidence that DLK activates JNK 
after RGC injury, which promotes apoptosis [1, 6]. JNK activation has also been 
implicated in photoreceptor apoptosis [7, 8]. DLK is a sunitinib target [9] and it was 
indirectly implicated to be one of sunitinib’s neuroprotective targets (Zhiyong Yang, 
unpublished data).  
The goal of this project was to evaluate sunitinib’s ability to protect 
photoreceptors in models of photoreceptor injury and to determine whether DLK is 
involved in photoreceptor degeneration. 
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Materials & Methods 
All animals used in this research were treated in accordance with the ARVO 
statement for the use of animals in vision research and all protocols were approved by 
Johns Hopkins’ institutional animal care and use committee. 
 
Kinase inhibitor intravitreal injections 
 Rodent – sunitinib 
A collaboration was established with Matthew LaVail at University of California 
in San Francisco where sunitinib was tested intravitreally in two rat models of autosomal 
dominant retinal degeneration (Rho S334ter and Rho P23H mutants). All animal 
husbandry, handling, treatments, tissue processing and morphological evaluation were 
performed at that institution. Rat pups were anesthetized with isoflurane and injected 
intravitreally with a Hamilton syringe (catalog #80337, Hamilton, Reno, NV) either once 
at p9 or twice at p9 and p12 (for Rho S334ter rats) and at p15 (for Rho P23H rats) with 2 
µL of sunitinib solution (see doses below). Animals were sacrificed at p19 and eyes were 
enucleated and fixed in a mixture of 2.5% glutaraldehyde and 2% paraformaldehyde. 
Globes were embedded in epoxy resin, and 1 µm thick sections were made along the 
vertical axis.  
At Johns Hopkins University, hemizygous Rho Q344ter mouse [10] pups and 
homozygous rd1 mouse pups between 10 and 11 days of age were anesthetized with a 
20% isoflurane/propylene glycol mixture and their eyelids were gently opened with 
curved forceps. The globe was proptosed and a hole made 0.5 to 1 mm behind the limbus 
with the tip of a 30 gauge needle in the upper temporal quadrant. The tip of a pulled glass 
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pipette containing drug solution was inserted into the hole and 1 µL of solution was 
injected using a pneumatic injector. Then the globe was replaced and triple antibiotic 
ophthalmic ointment was applied to the eyelids. Either uninjected or vehicle injected eyes 
served as untreated controls. The pups were allowed to recover in a heated box until they 
were mobile and then returned to the cage with their mothers, which was usually within 
15 minutes. At 17 or 18 days of age, the pups were anesthetized with isoflurane and then 
cervically dislocated. Globes were removed and fixed in either Bouin’s fixative overnight 
at room temperature or 4% PFA overnight at 4 oC. Globes were processed routinely, 
paraffin embedded, sectioned at 5 µm and stained with hematoxylin and eosin stain 
(H&E).  
 Rodent – DLK inhibitor 
Rho S334ter rat pups were injected with the DLK inhibitor at UCSF by Matt 
LaVail at p8 and sacrificed at p19. 
Hemizygous Rho Q344ter and homozygous rd1 mouse pups were injected with 
the DLK inhibitor at JHU at p11 and sacrificed at p17. There were only enough rd1 pups 
to test one dose. 
 Pigs 
In collaboration with Henry Kaplan at University of Louisville in Kentucky, a 
slow-release formulation of sunitinib was tested intravitreally in a transgenic minipig 
model of an autosomal dominant retinitis pigmentosa (RhoP23H) [11]. All animal 
housing, handling, dosing and testing was done at the University of Louisville. The 
piglets were either injected twice at p3 and p17 (five transgenic and three wild type) or 
injected once at p14 (six transgenic) and then all were sacrificed at p30. The left eye was 
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injected with sunitinib-containing microspheres at three different concentrations (1.056 
µg sunitinib/µL, 0.264 µg sunitinib/µL, 0.066 µg sunitinib/µL) and the right eye was 
injected with solutions containing the same amount of microspheres as the sunitinib 
loaded solutions. P3 animals received 50 µL of microsphere solutions and p14 and p17 
animals received 75 µL to adjust for eye growth. After euthanasia and enucleation, 
corneas were incised to allow for better fixation and globes submersion fixed in 4% PFA 
at 4 oC. Globes were processed routinely, paraffin embedded, sectioned at 5 µm and 
stained with H&E stain. 
 
Systemic treatment 
 Rho Q344ter and rd1 pups 
Intraperitoneal injections of sunitinib or vehicle (DMSO in PBS) were 
administered daily to pups from age p6 to p14. Pups were weighed daily to monitor 
growth and to dose them appropriately. Doses of sunitinib were 0, 5, 10, 15 (once daily) 
and 30 (every other day), 30 and 50 (daily) mg/kg. Pups were euthanized with isoflurane 
followed by cervical dislocation, enucleated and globes were fixed in 4% PFA overnight 
at 4 oC. Globes were processed routinely for paraffin embedding. Only one eye from each 




Slides were imaged at 100x with a Zeiss Axioplan 2 imaging system (Carl Zeiss 
Microscopy LLC, Thornwood, NY) and layer thicknesses were measured using Image J 
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(Abramoff 2004) for the sunitinib dosing. For the new DLK inhibitor evaluation, layers 
of nuclei in the ONL were counted manually in the retinas. 
 Rats 
The mean ONL thickness was obtained by taking an average of a total of 54 
measurements from the superior and inferior hemispheres (27 per hemisphere) using the 
Bioquant Morphometry System (R&M Biometrics, Nashville, TN). 
 Mice 
Three points between the optic nerve head (ONH) and the limbus were measured 
and averaged on both sides of the ONH for a total of six measurements per eye. For each 
point, the thickness of the outer nuclear layer (ONL) and the thickness of the outer border 
of the ONL from the inner border of the inner nuclear layer (INL) were measured. To 
avoid artifacts of a distorted retinal section, the ratio of the ONL to the ONL-INL 
measurement was reported. 
 Pigs 
Generally, twenty-four images were taken of each retina, two images from each of 
six points above and below the optic nerve head. Within each image, the retinal layers 
were measured (ONL and ONL-INL) at five points. Thus each location was measured ten 
times and then averaged. Some retinas could not be measured at all points due to artifact, 
which typically affected the more peripheral locations. 
 
Drug formulations 
Sunitinib malate (catalog # S-8803, LC Laboratories, Woburn, MA) was 
dissolved in DMSO and then further diluted in sterile PBS for injection. Intravitreal 
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injections in rats were 2 µL of 2, 10 and 20 mg/mL in 50% DMSO. Intravitreal injections 
in mice were 1 µL of either 0.156, 0.625, 2.5 or 10 mg/mL or 5, 10 and 20 mg/mL in 
50% DMSO. 
Sunitinib malate was formulated with PLGA (poly(lactic-co-glycolic acid)) into 
slow release microspheres (collaboration with Justin Hanes), which were used in the 
minipig injections. 
A new potent DLK inhibitor was developed and the information was released as a 
publicly available patent. Colleagues synthesized it and it was tested intravitreally at 
UCSF and JHU. Two doses were tested in rats (2 mM and 0.4 mM) and 3 in mice (0.5, 5 
and 50 µg). 
 
DLK western blotting 
Mice of various ages were euthanized via isoflurane followed by cervical 
dislocation, enucleated and retinas dissected in PBS. Individual retinas were 
homogenized in PBS and then an equal volume of Laemmli buffer (catalog # 1610737, 
BioRad Laboratories, Hercules, CA) with !-mercaptoethanol was added and 
homogenized and vortexed. Homogenates were stored at -80 oC and thawed when 
needed, heated to 100 oC for 5 minutes and then quantified using the EZQ™ Protein 
Quantitation Kit (catalog # R33200, Life Technologies, Carlsbad, CA). Samples were 
diluted to be approximately the same concentration, run in precast polyacrylamide gels 
(catalog # 345-0027, BioRad Laboratories, Hercules, CA) and transferred to  a 
nitrocellulose membrane (catalog # RPN203D, GE Healthcare, Pittsburgh, PA) using a 
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Criterion™ Cell/Plate Blotter System (catalog #165-6024, BioRad Laboratories, 
Hercules, CA). Each lane represents a retina from a single individual. 
Blots were blocked in TBST (TBS with 0.1% Triton X-100 (catalog # 
11332481001, Roche, Indianapolis, IN)) with 5% milk, washed and then individual 
primary antibodies were diluted in TBST with 5% milk and applied overnight at 4 oC. 
Primary antibody was washed in TBST, and then secondary antibody diluted in TBST 
with 5% milk was applied for one hour at room temperature and then washed in TBST. 
Blots were developed with SuperSignal Femto West Substrate (catalog # 34095, 
ThermoScientific, Waltham, MA) and imaged with an ImageQuant LAS4000 system (GE 
Healthcare, Pittsburgh, PA). Band densities were measured with Image J (Abramoff 
2004). Blots were stripped with Restore™ Western Blot Stripping Buffer (catalog # 
21059, ThermoScientific, Waltham, MA). Antibodies included: anti-Map3k12 (catalog # 
NBP2-17218, Novus Biologicals, Littleton, CO), anti-Gapdh (catalog # ab8245, Abcam, 
Cambridge, MA) and HRP-linked anti-mouse and HRP-linked anti-rabbit (catalog #s 
7076 & 7074 respectively, Cell Signaling Technology, Danvers, MA). 
 
Statistical tests 
Rat retinal thicknesses were analyzed with paired T tests. 
Mouse retinal thickness measurements were analyzed by multilevel linear mixed 
effects models with a random intercept for the animal to account for the correlations 






Based upon sunitinib’s neuroprotective effect on RGCs, we wanted to test the 
hypothesis that sunitinib might also promote photoreceptor survival. In collaboration with 
Dr. Matt LaVail (UCSF), sunitinib was tested in the rat transgenic autosomal dominant 
rhodopsin mutation (Rho S334ter) retinal degeneration model, which mimics the 
mutation in a form of human retinitis pigmentosa. The retinas of Rho S334ter rats are 
morphologically normal from birth to p10, at which point they begin to degenerate [12]. 
Wild-type and Rho S334ter rats were injected intravitreally with sunitinib, either once at 
P9 or at both P9 and P12. The highest dose of sunitinib (20 mg/mL) showed 
neuroprotective effects evidenced by a slowing of the rate of degeneration in the treated 
rats (Figure 1). The protective effect was more pronounced when rats received two 
injections (p9 and p12). Figure 1 shows retinal sections from representative rats and 
demonstrates that untreated retinas (A) only have one to two rows of nuclei in the ONL 
whereas twice-injected retinas (B) have three to four rows remaining. Some treated 
retinas had up to six rows of nuclei in the ONL (data not shown). A spider plot showing 
ONL thickness measurements at 21 points across the retina demonstrates that the twice-
injected retinas have a thicker ONL at all points measured. With all of the treated and 
untreated retinas combined, there was an overall statistically significant difference in 
ONL thicknesses between the two sets of retinas (Table 1) for both the once and twice 
injected eyes. Some sunitinib-treated and DMSO injected control eyes developed rosette-
like structures in the outer nuclear layer (Figure 1 D). 
Given the data demonstrating that sunitinib is neuroprotective for both RGCs and 
photoreceptors, that DLK inhibition promotes RGC survival, and that sunitinib is a potent 
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DLK inhibitor, it seemed reasonable to hypothesize that inhibition of DLK might also be 
neuroprotective for photoreceptor cells. To explore this hypothesis, I measured DLK 
expression in degenerating retinas. Figure 2 shows a western blot and the densitometric 
quantification of the amount of DLK protein in a time course of degenerating retinas 
from rd1 and hemizygous Rho Q344ter and age matched wild type mice. The results 
demonstrate that in both of the older ages in both RD models, there is increased DLK 
protein in the degenerating retinas compared to the age matched normal control retinas. It 
also demonstrates that at a point when very few rods remain in the rd1 retina (p20), there 
is still an elevated amount of DLK present, suggesting that DLK is being expressed by 
cells in addition to or other than rod photoreceptors. Additional western blots of 
degenerating retinal lysates run with 24 hours-in-culture RGC lysates as a positive 
control showed that the DLK present in whole retinal lysates ran slightly faster than the 
DLK present in RGCs (Figure 3). 
Given the elevation of DLK protein in degenerating mouse retinas and the 
evidence of neuroprotection of intravitreal sunitinib in the Rho S334ter rats, we designed 
and carried-out a number of experiments to test for neuroprotection in mouse models of 
retinal degeneration. Initially, we tested systemic drug administration. Sunitinib was 
administered intraperitoneally to homozygous rd1 and hemizygous Rho Q344ter mice. 
The first experiment used relatively high drug doses (30 and 50 mg/kg daily) and the 
pups did not survive long enough to evaluate their retinas at a point when neuroprotection 
could be evaluated (data not shown). The next attempt included lower doses (5, 10, 15 
mg/kg daily and 30 mg/kg every other day). Figure 4 shows the ratio of the ONL to 
ONL-INL measurement in one eye from each pup. There were no statistically significant 
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differences in any of the treatment groups, though there appeared to be a slight trend 
toward increased ONL thickness in the treatment group.  
Given that lack of sufficient drug delivery to the retina when administered 
systemically was one possible explanation as to why no neuroprotection was observed, 
we next pursued intravitreal injection. Figures 5 and 6 show the ratios of ONL to ONL-
INL layer thicknesses from two different experiments in which sunitinib was injected 
intravitreally. There were no significant differences in the means of any of the treatment 
groups in either experiment. Multiple eyes from those reported in Figure 5 had injection 
artifacts including cataract, debris and inflammatory cells in the vitreous, pre-retinal 
fibrovascular membrane, focal retinal thinning and occasional retinal rosettes. The eyes 
reported in Figure 6 had no artifacts attributed to the injections, but also did not show any 
protective effect with any of the tested doses of sunitinib. A possible explanation for the 
lack of observed neuroprotection in these experiments is that due to pharmacokinetic 
issues, even thought a single injection was protective in the rat Rho S334ter model, a 
single injection may not provide sufficient sustained levels of drug over time in the 
mouse eye. 
An opportunity arose to try a slow-release formulation of sunitinib (sunitinib 
loaded PLGA microspheres, collaboration with Dr. Justin Hanes) in a mini-pig model of 
autosomal dominant rhodopsin mutation (Rho P23H) in collaboration with Henry Kaplan 
at the University of Louisville [11]. When the pigs were evaluated with spectral domain 
optical coherence tomography (SD-OCT) the injected bolus of microspheres was 
visualized as a focal opaque accumulation of material in the vitreous in the pigs that 
received the highest dose of microspheres. These accumulations of microspheres were 
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still visible when the eyes were hemisected for processing. Though some regions of the 
retinas (mostly peripheral) showed significant differences between right (blank 
microspheres) and left (sunitinib-containing microspheres), there were no consistent 
differences across the entire retina of any individual. Figure 7 shows representative data 
from two pigs (one wildtype and one transgenic) that received the highest dose of 
sunitinib.  
Because of the interest in DLK as a neuroprotective agent, additional DLK 
inhibitors have been developed. A new potent DLK inhibitor was synthesized at JHU 
based upon a published patent application and tested in both Rho S334ter rats (through 
the collaboration with Dr. LaVail) and in the Rho Q344ter mice at JHU. There was a 
small but significant difference in the rat eyes that received the 2 mM dose compared to 
the uninjected eyes (P = 0.0460), but not the 0.4 mM dose (Table 2 and Figure 8). There 
was no significant difference in any of the doses compared to the uninjected eyes in the 
Rho Q344ter mice (P > 0.05); however, there was a significant difference in the rd1 eyes 
that received 5 µg compared to those that were uninjected (P = 0.033) (Figure 9). 
 
Discussion 
Sunitinib is a multiple kinase inhibitor that showed promising neuroprotective 
effects in retinal ganglion cells (RGCs) both in vitro and in vivo (Zhiyong Yang 
unpublished data). This led to a collaboration with Dr. Matthew LaVail, which showed 
that sunitinib also exhibited promising and statistically significant PR survival promoting 
activity in the context of photoreceptor degeneration in the Rho S334ter rat, a model of 
autosomal dominant retinitis pigmentosa (Table 1 and Figure 1). As the function of the 
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photoreceptors was not evaluated in this study, it is unknown if there was any rescue of 
photoreceptor function. The dose that had neuroprotective effects (2 µL of 20 mg/mL) 
was extremely high, and given that it was not administered as a slow release formulation, 
its success is surprising. There were some signs of possible toxicity evidenced by retinal 
rosette formation in some of the rats, although at least some of this rosette forming 
activity appeared to be related to the DMSO vehicle. 
Because of the recent discovery of DLK’s involvement in the death of injured 
neurons including RGCs [1, 6, 13, 14], DLK protein levels were measured in retinas 
undergoing photoreceptor degeneration. An elevation of DLK protein was confirmed in 
degenerating retinas at several time points; however, its elevation was also present after a 
point at which very few photoreceptors remained, suggesting that the DLK was present in 
another retinal cell (perhaps in addition to photoreceptors) (Figure 2). Because DLK was 
measured in whole retinal lysates, it was not possible to determine which cell type was 
accumulating DLK protein. Future studies could utilize flow sorting of various 
subpopulations of retinal cells from degenerating retinas to determine from where the 
elevation in DLK originates. Even if the DLK is present in a cell type other than PRs, it is 
possible that DLK inhibition could still promote PR survival. 
Of potential interest, the RGC positive control DLK runs slightly more slowly 
than that of the degenerating retinal lysates (Figure 3). Though the reason for this is 
unknown, it is possibly due to the phosphorylation of DLK in injured RGCs similar to 
that reported in dorsal root ganglia (DRG) neurons when nerve growth factor (NGF) is 
withheld [13]. In this model, a decrease in available NGF leads to local DLK activation, 
which in turn activates JNK, which then phosphorylates and thus stabilizes DLK, 
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allowing DLK accumulation and further activation of a stress response. DLK in lysates 
from degenerating retinas runs more slowly than that of DLK from injured RGCs, which 
could be because DLK is not being phosphorylated in degenerating retinas as happens in 
injured DRG neurons. This could mean that DLK is accumulating by a different as of yet 
unidentified mechanism.  
The promising results in the Rho S334ter rats coupled with the elevated levels of 
DLK in degenerating retinas warranted further testing of sunitinib. It was tested using 
several different techniques in mouse models of retinal degeneration. From Zhiyong 
Yang’s unpublished work with sunitinib, it was known that systemically delivered 
sunitinib was protective for RGCs in an adult mouse model of optic nerve injury; 
therefore, our first experiment testing sunitinib in models of retinal degeneration utilized 
daily systemic delivery in mouse pups at a number of different doses beginning at p6, an 
age before any morphological evidence of degeneration is recognizable.  One of the 
models tested was the mouse equivalent of the Rho S334ter rat (Rho Q344ter) at multiple 
doses and the other was the rd1 mouse strain. The initially tested higher doses (30 and 50 
mg/kg daily), which are doses that have been active in other models, resulted in toxicity 
and the pups died after 2-4 days of treatment. The second experiment in which no 
significant toxicity was noted, failed to demonstrate neuroprotection in that the retinas of 
the treated animals had the same ONL thickness ratio as the vehicle treated animal 
(Figure 4). Because the delivery of sunitinib to the retina was never confirmed, it was 




Using a range of doses of intravitreal sunitinib in two different experiments in the 
Rho Q344ter mouse strain, we did not observe any evidence of neuroprotection in the 
sunitinib injected animals. The first experiment (Figure 5) resulted in a number of toxic 
effects and/or injection artifacts (data not shown). The second experiment (Figure 6), had 
none of these negative effects, but still failed to show evidence of neuroprotective effects, 
even though the same dose was tested that Dr. LaVail used that showed neuroprotection 
in the rat model. The reason for this difference remains unclear, but could reflect 
differences in pharmacokinetics between rat and mouse eyes. 
In a pilot study, a slow release formulation of sunitinib was tested in a minipig 
model of autosomal dominant retinal degeneration (Figure 7). No attempt was made to 
confirm sunitinib delivery to the photoreceptor layer of the retina. The behavior of the 
microspheres was unknown in an eye as large as a pig eye, though they had shown 
efficacy in a rat model of glaucoma (Zhiyong Yang, unpublished data). The lack of 
dispersal of the microspheres at the highest doses was an unexpected result. It is possible 
that a significant amount of the sunitinib was sequestered in these accumulations and was 
unable to diffuse properly to the photoreceptor layer. In the 11 transgenic minipigs that 
received sunitinib in three different doses, none of them showed consistent 
neuroprotection regardless of whether they received one or two injections, although some 
local and not statistically significant areas of increased ONL thickness were observed. It 
is possible that drug delivery to the pig retina was a problem despite receiving an 
intravitreal injection. 
We also tested a new DLK inhibitor. It was tested intravitreally in both rats 
(UCSF) and mice (JHU). This new compound demonstrated neuroprotection in the Rho 
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S334ter rat model (Table 2 and Figure 8). It also showed mild neuroprotection in two rd1 
mice but not in any of the Rho Q344ter mice tested (Figure 9). These results provided 
additional support that DLK inhibition may be beneficial in photoreceptor degeneration. 
There are no published reports of DLK being involved in modulating 
photoreceptor survival, though it is known to be involved in not only RGC death, but also 
dorsal root ganglion neurons [1, 15]. DLK is upstream of the JNK pathway that leads to 
apoptosis in neuronal cells. Of the myriad studies characterizing photoreceptor cell death 
in retinal degeneration, a few have implicated JNK activation as contributing to 
photoreceptor death [7, 8]. If there is a similar connection between DLK and JNK 
activation in degenerating photoreceptors as there is in RGCs and cortical neurons, it is 
possible that DLK inhibition could potentially lessen photoreceptor death in 
degeneration. The studies described here involving the Rho S334ter rat model of retinal 
degeneration showed positive effects when sunitinib or the potent novel DLK inhibitor 
were administered; however, this was not recapitulated in a number of different mouse 
models of retinal degeneration. It is possible, but probably unlikely, that the 
photoreceptor cell death mechanism in the Rho S334ter rat differs greatly from that of the 
Rho Q344ter mouse, which might help to explain the difference in response to sunitinib 
and DLK inhibitor administration. It seems more likely that issues of drug delivery and 
metabolism may account for the observed differences. 
If it turns out that DLK is not involved in photoreceptor degeneration, this would 
suggest that sunitinib’s ability to promote photoreceptor cell survival is due to inhibition 
of one or more other kinases. If that other kinase(s) can be determined, such identification 
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could provide a novel target(s) for the development of drugs that prevent or slow down 
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ONL thickness (µm) 
Mean +/- St dev 
DMSO injected 
eyes ONL thickness 
(µm) 
Mean +/- St dev 
Paired t-test results 
Sunitinib single 
injection (N = 5) 18.0 +/- 7.0 8.6 +/- 0.5 0.038 
Sunitinib two 
injections (N = 6) 13.7 +/- 3.3 8.5 +/- 1.2 0.0069 
 
Table 1. Retinal thickness measurements in Rho S334ter mutant rats treated with 
intravitreal sunitinib. The photoreceptor degeneration of Rho S334ter rat retinas 
injected with 2 µL of 20 mg/mL sunitinib either once or twice was slower than uninjected 
control eyes. Six animals received a single injection at p9 and five animals received two 
injections (at p9 and p12). All animals were sacrificed at p19. Eyes that received either 
one or two injections of sunitinib had a statistically significantly slower degeneration 






Rows of nuclei in 
the ONL 
Mean +/- St dev 
Uninjected eyes 
Rows of nuclei in 
the ONL 
Mean +/- St dev 
Paired t-test results 
Novel DLK 
inhibitor (N = 4) 2.8 +/- 0.79 1.5 +/- 0.26 0.0460 
 
Table 2. Rows of photoreceptor nuclei in Rho S334ter mutant rats injected with a 
novel DLK inhibitor. The photoreceptor degeneration of Rho S334ter rat retinas injected 
with 2 µL of 2 mM of a novel DLK inhibitor was slowed. Four animals received the 
DLK inhibitor at p8 and then all were sacrificed at p19. Eyes that received the novel 




Figure 1. Representative retinal sections from Rho S334ter rats treated with 
sunitinib and ONL thickness measurements. A. Retinal section from a DMSO treated 
retina from a Rho S334ter rat sacrificed at p19. B. Representative retinal section from a 
Rho S334ter rat that received 2 µL of 20 mg/mL intravitreal sunitinib at p9 and p12 and 
then sacrificed at p19. Note that there are more photoreceptors remaining in the sunitinib 
treated eye than in the untreated retina. Plastic embedded, toluidine blue stained sections. 
C. Spider plot showing measurements of ONL thickness in a representative rat treated 
with 20 mg/mL of sunitinib at p9 and p12 and sacrificed at p19. The treated eye has a 
thicker ONL at all points measured compared to the untreated eye. Error bars represent 
the standard errors of the mean. D. Rosettes developed within the ONL in some eyes that 
received sunitinib. Similar rosettes developed in some eyes that received vehicle (DMSO) 
only as well as some eyes that received sunitinib. RPE = retinal pigmented epithelium, 
ONL = outer nuclear layer, INL = inner nuclear layer.
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Figure 2. Western blot of DLK protein in degenerating mouse retinas. Blot 
demonstrates DLK protein levels in degenerating and age matched wild type whole 
retinal lysates from homozygous rd1 and hemizygous Rho Q344ter mice. Top panel 
shows the blot for DLK with GAPDH as a loading control. Bottom panel shows the 
density of the DLK bands from the above blot normalized to the GAPDH bands as 
measured with Image J. Note that at the older ages for both strains, there is an increase in 





















are very few rods remaining, however, there is still an elevated amount of DLK protein 
present indicating the DLK protein is likely coming from cells other than photoreceptors. 
Qter p17 retinas have 4-6 rows of nuclei remaining in the ONL compared to 16-20 in the 
wild type, and therefore the DLK present in hemizygous Qter retinas at p17 could be 
from photoreceptors in addition to other retinal cells.  Each lane represents retinal lysates 





Figure 3. Western blot of DLK protein in Rho Q344ter mouse retinas and wild type 
mouse neurotrophin-starved RGCs. Qter whole retinal lysates are from 17 and 19 day 
old mouse pups and RGC lysate is from cells in culture for 24 hours without 
pharmacological or neurotrophic support.  The DLK band in retinal lysates travels faster 











Figure 4. ONL : ONL-INL ratio after daily systemic delivery of sunitinib to 
hemizygous Rho Q344ter (Qter) mice and homozygous rd1. Pups were injected daily 
with sunitinib from p6 to p14 and then sacrificed on p15. Layer thicknesses were 
measured in paraffin embedded, hematoxylin and eosin-stained sections (one section 
from one eye from each mouse) at three points on both sides of the optic nerve head (six 
points total) and averaged for the whole eye. Error bars represent the standard deviations. 
There was no significant difference in any of the treatment groups compared to the 
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Figure 5. ONL : ONL-INL ratio after intravitreal injection of sunitinib in 
hemizygous Rho Q344ter (Qter) or wildtype mice.  A single injection of sunitinib or 
vehicle was given to p11 pups, which were then sacrificed at p18 and retinas measured in 
paraffin embedded, hematoxylin and eosin stained sections. Each bar represents the 
average of two (0.156 mg dose) or three (Vehicle, 0.625, 2.5, 10 mg dose) eyes with the 
standard deviation. There was no significant difference in any of the treatment groups 
























Figure 6. ONL : ONL-INL ratios from hemizygous Rho Q344ter mice treated with 
intravitreal sunitinib. The left eye of each pup was injected with sunitinib and the right 
eye was uninjected and served as a negative control. Pups were injected intravitreally at 
p11 and then sacrificed at p17. Layer thicknesses were measured in paraffin-embedded, 
hematoxylin and eosin stained sections. Each bar represents the average of measurements 
of all eyes in the treatment group with the standard deviation. There was no significant 
difference in any of the treatment groups compared to the uninjected eye (P > 0.05). No 
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Figure 7. ONL : ONL-INL ratio in a wild-type and a hemizygous Rho P23H minipig 
treated with intravitreal slow release sunitinib. Piglets were injected intravitreally at 
p3 and p17 and then sacrificed at p30. Left eyes (OS) received sunitinib containing 
microspheres and right eyes (OD) received blank microspheres. A. Measurements from a 
wild-type piglet. B. Measurements from a transgenic Rho P23H piglet. Note that there 
were no apparent toxic effects in the wild-type pig, but there was also no protective effect 
in the transgenic piglet. 
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Figure 8. Representative retinal sections from Rho S334ter rats treated with a novel 
DLK inhibitor. Images represent retinas from a Rho S334ter rat eye that received the 
new small molecule (A) and an uninjected control retina (B). Pups were injected 
intravitreally at p8 with 2 µL of a 2 mM solution and then sacrificed at p19. The retina 
that received the DLK inhibitor (A) had three to four rows of nuclei in the outer nuclear 
layer (ONL) compared to the uninjected retina (B), which had only one to two rows of 






Figure 9. Results of the intravitreal injection of DLK inhibitor in hemizygous Rho 
Q344ter (Qter) and homozygous rd1 mouse pups. The left eye of each pup was 
injected with the DLK inhibitor and the right eye was uninjected and served as a negative 
control. Pups were injected intravitreally at p11 and then sacrificed at p17. Layer 
thicknesses were measured in paraffin-embedded, hematoxylin and eosin stained sections 
Each bar represents the average of measurements of all eyes in the treatment group with 
the standard deviation. Single factor ANOVA reported no significant difference in the 
means of the Qter animals  (P > 0.05). However, the rd1 animals that received 5 µg of the 
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P = 0.033 
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Chapter 2: Exploration of whether Parp1 knockout promotes photoreceptor 
survival in murine models of retinal degeneration  
 
Introduction 
Poly (ADP-ribose) polymerase 1 (PARP1) is an enzyme that is involved in many 
different cellular processes, but is especially well known for its role in sensing DNA 
damage and initiating DNA repair. Interest in PARP1’s role in neuronal cell death has 
increased in the past several years since its excess activation was recognized as playing a 
role in neuronal cell death in a process termed “parthanatos” (reviewed by Andrabi [1] 
and Fatokun [2]). DNA damage activates PARP1, which transfers ADP-ribose from 
nicotinamide adenine dinucleotide (NAD+) to other proteins as well as itself [3, 4]. 
Excess poly-ADP-ribose (PAR) accumulation in the cytoplasm leads to translocation of 
apoptosis-inducing factor (AIF) from the mitochondria to the nucleus, initiating DNA 
cleavage. Additionally, PARP1 activation can lead to a depletion of NAD+, which further 
contributes to cell death. 
The role of PARP1 activation in retinal degeneration has been investigated by 
several groups. Photoreceptor cell death induced by N-methyl-N-nitrosurea (MNU), a 
DNA alkylating agent known to induce apoptosis in photoreceptors [5], can be prevented 
by both pharmacological PARP inhibition and supplementation with nicotinamide [6, 7]. 
An increase in PARP activity and PAR formation was found in Pde6b mutant mice (rd1) 
in the later stages of retinal degeneration, which correlated with oxidatively-damaged 
DNA and nuclear translocation of AIF [8]. Additionally, treatment with a PARP-specific 
inhibitor (PJ34) decreased cell death and resulted in more surviving photoreceptors in an 
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rd1 retinal explant culture system [8]. The detrimental effects of zaprinast, a PDE 
inhibitor that mimics photoreceptor cell death induced by Pde6b mutation, were 
decreased in a Parp1 KO retinal explant system [9].  
Because of the implication of PARP1 activity in photoreceptor degenerations, 
further investigations utilizing Parp1 knockout (KO) mice were performed. Parp1 KO 
mice were found to be resistant to MNU-induced photoreceptor degeneration up to 72 
hours post-injection as evaluated by electroretinography (ERG) and spectral-domain 
optical coherence tomography (SD-OCT) (Xinrong Zhou, unpublished data, not shown). 
The effect of Parp1 KO was evaluated after sodium iodate (NaIO3) administration and 
also in the face of Pde6b-mutation induced retinal degeneration (rd1), with the 
hypothesis that Parp1 KO would be protective in these two different retinal degeneration 
models. 
 
Materials & Methods 
All animals used in this research were treated in accordance with the ARVO 
statement for the use of animals in vision research and all protocols were approved by 
Johns Hopkins’ institutional animal care and use committee. The Parp1 KO mice were a 
gift from Valina Dawson. 
 
Sodium iodate (NaIO3) injections 
Adult Parp1 KO and Parp1 wild type (WT) mice were injected intravenously via 
the tail vein with vehicle only (PBS), 20 or 40 mg/kg of NaIO3 and euthanized with an 




Parp1 KO / rd1 cross 
Parp1 KO mice were bred to rd1 mice and then F1 offspring were bred to obtain 
various genotype combinations. Offspring of these F2 crosses were evaluated at 14, 15, 
16 and 17 days of age via retinal morphology. Pups were euthanized with an isoflurane 
overdose followed by cervical dislocation. 
 
Tissue processing and image analysis 
Following euthanasia, globes were collected, fixed in 4% paraformaldehyde 
overnight at 4 oC, routinely processed for paraffin embedding, sectioned at 5 µm and 
stained with hematoxylin and eosin. Slides were imaged at 100x with a Zeiss Axioplan 2 
imaging system (Carl Zeiss Microscopy LLC, Thornwood, NY) and measurements taken 
using Image J [10]. Because of the undulating contour of the retinal layers after sodium 
iodate injection, simply measuring the layer thicknesses was insufficient. Instead, the area 
of the ONL was divided by the length of the measured retina. To evaluate the retinas of 
the genetic crosses of the Parp1 KO and rd1 mice, three points between the optic nerve 
head (ONH) and the limbus were measured and averaged on both sides of the ONH for a 
total of six measurements per eye. For each point, the thickness of the outer nuclear layer 
(ONL) and the thickness of the outer border of the ONL from the inner border of the 
inner nuclear layer (INL) were measured. To avoid artifacts of a distorted retinal section, 






Retinal thickness measurements of the Parp1/rd1 animals were analyzed by a 
multilevel linear mixed effects model with a random intercept for the animal to account 
for the correlations among the repeated measures from the same animal.  
 
Results 
Sodium iodate damages RPE cells and causes a secondary photoreceptor 
degeneration [11]. Though the Parp1 KO mice were shown to be resistant to MNU-
induced photoreceptor damage in the short term, it was unknown whether photoreceptors 
from Parp1 KO mice would be resistant to later degeneration. At 36 days post-injection 
we did not see evidence of increased photoreceptor survival in the Parp1 KO mice. In 
fact, although not statistically significant, the Parp1 KO mice showed more severe retinal 
degeneration in response to sodium iodate than the WT mice (Figure 1). However, there 
were likely technical issues with the experiment, as sodium iodate injection did not 
consistently induce ONL depletion in the WT mice.  
The retinal thicknesses of a total of 30 animals of varying Parp1 KO / rd1 
genotypes were evaluated. All of the rd1 heterozygous animals’ ONL:ONL-INL ratios 
were over 0.5 (data not shown), whereas those of rd1 homozygous animals were all under 
0.4 (Figure 2). Figure 2 shows all of the rd1 homozygous animals analyzed and their 
Parp1 status. The animals in three of the five litters showed a significant difference 
between Parp1 -/+ (het) and Parp1 -/- (KO) in the face of rd1 induced retinal 





There has been increasing interest in PARP’s role in retinal degeneration in the 
past several years, and these experiments were meant to further investigate the effect of 
Parp1 KO on retinal degeneration. 
The results of the sodium iodate injections were interesting in that not only did 
Parp1 KO not protect against retinal degeneration, but seemed to result in greater 
degeneration (more severe ONL depletion) compared to wild type animals. Though 
Parp1 KO was protective against MNU in a short term study (72 hrs), it was not 
evaluated at later time points following MNU injection. The sodium iodate experiment 
was carried out to 36 days post-injection without earlier evaluation. It is possible that the 
different time points of evaluation of the MNU and sodium iodate experiments can 
account for the differences seen (lack of protection from sodium iodate at 36 days post-
injection). It is possible that Parp1 KO retinas may eventually succumb to MNU-induced 
photoreceptor degeneration at later time points. It is also possible that the Parp1 KO 
retinas may be resistant to initial damage caused by sodium iodate. Additional MNU and 
sodium iodate administration experiments should be repeated with similar evaluation 
time points to address this in the future.  
The variation in photoreceptor degeneration of the Parp1 WT animals that 
received sodium iodate suggests that technical issues with the drug administration may 
have played a role. Additionally, mice of a range of ages (4 to 20 weeks) were included 
in the study, which may have contributed to the observed experimental variability. 
Animals in three of five evaluated litters of Parp1 / rd1 crosses showed a 
significant difference between Parp1 -/- / rd1 homozygous and Parp1 +/- / rd1 
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homozygous. This result was with a relatively small number of animals; however, it does 
suggest that Parp1 KO can be mildly protective against photoreceptor loss in the rd1 
model. Why some liters showed evidence of protection and others didn’t is unclear. It 
doesn’t appear that the age of the animals explains the difference since there were two 14 
day-old litters, with one showing a statistically significant increase in survival and one 
not showing a significant difference. The finding of protection in some of the animals is 
consistent with the published findings that Parp inhibition in rd1 explants increased the 
number of surviving photoreceptors [8]. These findings are also consistent with the report 
that photoreceptors from Parp1 KO mice were partially resistant to treatment with 
zaprinast, which is a PDE6B inhibitor that mimics the rd1 mutation [9]. These results, 
taken together with the published literature, suggest that Parp1 KO is protective against 
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Figure 1. Morphological measurements of Parp1 KO and WT retinas after sodium 
iodate injection. Parp1 KO was not observed to be protective against systemic sodium 
iodate at 36 days post-injection. However, the sodium iodate injection did not 
consistently induce ONL depletion in WT mice, indicating possible variation in drug 
administration, or perhaps another experimental variable that was not determined. The 
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Figure 2: Morphological measurements of Parp1/rd1 mutant animals. Animals 
heterozygous and homozygous for the Parp mutation in the face of homozygous Pde6b 
mutation (rd1) suggests Parp1 KO may be protective. Each individual marker represents 
measurements from a single eye of an individual animal. Each grouping of ages 
represents animals from a single litter. There were two litters collected at 14 days of age 
– one showed significant protection, and one did not. * = significant difference between 
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EDUCATION 
• Comparative Ocular Pathology Laboratory of Wisconsin, University of 
Wisconsin, School of Veterinary Medicine, Madison, WI 
o July 2014 to present 
o Pathology Fellow: I am a trainee in the lab of a very busy mail-in 
biopsy service that receives ocular pathological specimens from 
veterinary ophthalmologists and veterinarians from all over the world. 
Duties include grossing specimens as they arrive, histological 
evaluation and report writing. 
 
• Cellular and Molecular Medicine Graduate Program, Johns Hopkins University, 
School of Medicine, Baltimore, MD 
o August 2008 to present 
o PhD Candidate in Donald Zack’s laboratory: I am analyzing 
important promoter elements for retinal ganglion cell and 
photoreceptor enriched genes. 
 
• Molecular and Comparative Pathobiology, JHU, SOM, Baltimore, MD 
o July 2007 to June 2014 
o Postdoctoral Veterinary Pathology Trainee:  Duties included gross 
and histopathological examination of animals and biopsies from JHU, 
National Aquarium in Baltimore, Maryland Zoo in Baltimore and 
outside veterinary clinics and participating in relevant veterinary 
pathology training including a weekly slide conference 
 
• Michigan State University College of Veterinary Medicine, East Lansing, MI 
o Degree awarded: DVM, May 2007 
o Cumulative GPA 3.68 / 4.0 
 
• Michigan State University Comparative Medicine and Integrative Biology 
      Graduate Program, East Lansing, MI  
o Degree awarded: MS, August 2007 
o Thesis: Further characterization of the retinopathy, globe-enlarged 
chicken 
o Cumulative GPA 3.92 / 4.0 
 
• Kalamazoo College, Kalamazoo, MI 
o Degree awarded: BA Biology, June 2001 




• Comparative Ophthalmology Laboratory, MSU CVM, East Lansing, MI 
o May 2004 to August 2007 
o Master’s student:  My project encompassed the further 
characterization of the retinopathy, globe-enlarged (rge) chicken and 
includes immunohistochemistry, gene hunting, electron microscopic 
analysis and electroretinography.  Duties also include supervising the 
maintenance of the rge chicken flock at MSU. 
o Research funded by NIH T-32 Student Research Training Grant 
 
• USDA Avian Disease and Oncology Laboratory, East Lansing, MI  
o May 2003 to August 2003 
o Research Assistant: Aided in furthering the diagnosis of Marek’s 
Disease in chickens using immunohistochemistry and real time PCR 
o Experience funded by an NIH T-35 Summer Research Grant 
 
 
• Veterinary Parasitology Laboratory, Ohio State College of Veterinary 
      Medicine, Columbus, OH 
o June through July 2000 
o Research Assistant: Tested fenbendazole and its efficacy against the 
common gastrointestinal parasites of llamas and alpacas.  
o Duties included restraining the animals and collecting, setting up and 
analyzing fecal samples.  Results were submitted to fulfill Kalamazoo 
College’s required Senior Individualized Project. 
 
 
• Barking Dogs in Kennel Settings Research Project, Perth, Western Australia 
o August to November 1999 
o Research Assistant:  Project determined that barking dogs in kennel 
settings in veterinary clinics and animal shelters is hazardous to human 
hearing.   
o Duties included taking measurements of dogs barking using a decibel 
meter, determining whether they were hazardous to human hearing and 
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Retinal Ganglion Cell (RGC) Transcriptional Regulation ARVO Meeting 
Abstracts March 26, 2012 53:1533 
 
• Baxter VK, Shaw GC, Sotuyo NP, Carlson CS, Olson EJ, Zink MC, Mankowski 
JL, Adams RJ, Hutchinson EK, Metcalf Pate KA. Serum albumin and body 
weight as biomarkers for the antemortem identification of bone and 
gastrointestinal disease in the common marmoset. PLoS One. 2013 Dec 
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POSTER / ORAL PRESENTATIONS 
 
• Association for Research in Vision & Ophthalmology, May 2013  
o Poster Presentation: Transcriptional regulation of synaptotagmin 11 in retinal 
ganglion cells 
 
• Association for Research in Vision & Ophthalmology, May 2012 and 23RD 
Annual Wilmer Research Meeting, April 2012  
o Poster Presentation: Synaptotagmin 11: A Model for the Study of Retinal 
Ganglion Cell (RGC) Transcriptional Regulation 
 
• 62nd annual meeting of the American College of Veterinary Pathology, December 
2011 
o Case presentation at the Ocular Pathology Mystery Slide Conference: Corneal 
stromal defect and ectasia (staphyloma), with iris prolapse, broad anterior 
synechia and Descemet’s membrane rupture in a Chihuahua 
 
• 17th Annual CL Davis Zoo & Wildlife Pathology Workshop at the 43rd Annual 
meeting of the American Association of Zoo Veterinarians, October 2011 
o Oral presentation: Metabolic Bone Disease in a Common Marmoset 
 
• 61st annual meeting of the American College of Veterinary Pathology, October 
and November 2010 & 22nd Annual Wilmer Research Meeting April 2011 
o Poster: Regulation of retinal ganglion cell gene expression: development of an 
electroporation-based method for the study of cis-acting regulatory elements 
 
• 60th annual meeting of the American College of Veterinary Pathology, December 
2009 
o Poster: Metabolic bone disease in a colony of common marmosets (Callithrix 
jacchus) 
 
• 59th annual meeting of the American College of Veterinary Pathology, November 
2008 
o Poster: Chitinolytic Shell Disease and Branchitis in Captive American 
Horseshoe Crabs (Limulus polyphemus) 
 
• 15TH annual CL Davis Zoo & Wildlife Pathology Workshop at the 40th Annual 
      meeting of the American Association of Zoo Veterinarians, October 2008 
o Oral Presentation: Ocular Mycobacteriosis in a Madagascar Tomato Frog 
 
• Phi Zeta Research Day (MSU CVM) 2005 
o Poster: The search for the gene and causative mutation responsible for the 




• ARVO (Association for Research in Vision and Ophthalmology) 2005, Phi Zeta 
Research Day (MSU CVM) and the Merck-Merial Student Research  Symposium 
2005 
o Poster: Pharmacological dissection of the electroretinogram of the 
Retinopathy, globe-enlarged (rge) chicken 
 
• Phi Zeta Research Day (MSU CVM) 2003  
o Poster: New techniques for the diagnosis of Marek’s disease in chickens 
 
AWARDS 
• NIH Loan Repayment Program, July 2012-June 2014 
• K12 Award through Wilmer Eye Institute, October 2011 – June 2014 
• Young Investigator  Award, category of Natural Disease, Second place for poster 
entitled “Metabolic bone disease in a colony of common marmosets (Callithrix 
jacchus)”, 60th Annual meeting of the American College of Veterinary 
Pathologists, December 2010 
• Young Investigator  Award, category of Diagnostic Pathology, Third place for 
poster entitled “Chitinolytic Shell Disease and Branchitis in Captive American 
Horseshoe Crabs (Limulus polyphemus)”, 59th Annual meeting of the American 
College of Veterinary Pathologists, November 2008 
• CVM General Scholarship, 2006 
• Salsbury Scholarship, 2006 
• Member of The Phi Zeta Honorary Society of Veterinary Medicine, 2006 
• NIH T-32 Training Grant, 2005 
• NIH T-35 Training Grant, 2003 
• Merck/Tanaka Award for Veterinary Sciences, 2003 
• Veterinary Camp Scholarship, 2002 




• Ocular Pathology Lectures 
o Pathology for Graduate Students: Basic Mechanisms (300.713), 2008, 
2009, 2010, 2011, 2012, 2013 
o Comparative Pathobiology & Genetically Engineered Mice (680.701), 
Johns Hopkins School of Medicine, 2010, 2012 
o Ophthalmic Phenotyping of Mutant Mice for the JHU Mouse 
Pathobiology and Phenotyping Short Course, 2012, 2013 
 
• Mouse dissection lab 
o 2010, 2011, 2012 Mouse Pathobiology and Phenotyping Course 
 
• Toxicological Pathology of the Eye Lecture 
o Environmental Toxicological Pathology (187.620.01), Johns Hopkins 
School of Public Health 2010, 2011, 2012, 2013 
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• Mouse model of asthma lecture 
o Comparative Pathobiology & Genetically Engineered Mice, May 2008 
 
• Veterinary Microbiology Tutor, MSU CVM, East Lansing 
o January to May 2004 
o Tutor: Individually tutored a student to help him understand the most 
important aspects of veterinary microbiology 
 
• Veterinary Histology Teaching Assistant, MSU CVM, East Lansing 
o August to December 2003 
o Teaching Assistant: Helped first year vet students identify cells and 
tissues as they navigated the histology laboratory exercises 
 
CLINICAL VETERINARY EXPERIENCE 
• Maryland SPCA, Baltimore, MD 
o January 2008 to June 2014 
o Veterinarian: Spay, neuter & vaccinate feral cats 
 
• Milwood Animal Clinic, Portage, MI  
o February 2001 to July 2002 
o Small Animal Veterinary Technician: Checked in animals for surgery, 
prepared pre-surgical meds, induced and monitored anesthesia, 
assisted in surgery, communicated with clients, phlebotomy, 
radiographed, stocked, tracked items to be ordered, weekend care of 
in-house patients and general restraint of small animals including 
exotics 
 
• Emergency Pet Clinic, Inc., Bedford Hts, OH 
o June ‘98 to Aug. ‘98, Dec. ‘98, June ’99, Aug. ’00, Dec. ‘00  
o Veterinary Technician:  Answered the phone, communicated with 
clients, restrained animals for examination, administered treatments, 
filled prescriptions, took radiographs, used automatic blood analyzing 
machines and took care of patients in the clinic. 
 
• Western Australian Rural Sheep Farms, Western Australia 
o January 2000 
o Veterinarian/Farm Consultant’s Assistant:  Restrained and mustered 
sheep during shearing, collected blood samples for selenium trials, 
collected and analyzed fecal samples, and learned how to work with 










• Mary Rheuben’s Residence, Holt, MI 
o May 2003 to May 2006 
o Manual Laborer:  Duties include cleaning horse stalls, managing 
manure, sheep work (vaccinating, deworming, feeding), mowing the 
lawn, planting and weeding both vegetable garden and flower beds and 
other tasks as needed. 
 
• Nutrition Kitchen Care Taker, Veterinary Teaching Hospital, East Lansing, MI 
o November 2002 to March 2004 
o Cleaner and Stocker: Duties included keeping the nutrition kitchen 
clean, stocking canned and dry dog and cat food and managing the 
hospital’s inventory of available pet foods.  
 
• Center for International Programs, Kalamazoo College, Kalamazoo, MI 
o September 2000 to June 2001 
o Peer Advisor: Duties include helping students learn about and choose a 
study abroad program, advising them in the application process and 
preparing them for their experiences abroad. 
 
• Residential Life, Kalamazoo College, Kalamazoo, MI 
o September 1998 to June 1999 and March 2000 to June 2000 
o Residential Advisor:  Duties included being a resource person for the 
first year students, keeping order in the residence halls and 
programming activities for residents. 
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